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The fetus is exposed to many 
chemicals during pregnancy. In 
the present study, human placental 
perfusion was used to determine 
placental toxicokinetics of several 
chemical carcinogens. All of the 
studied compounds crossed the 
placenta although there were dif-
ferences in their transfer rates. 
This study confirmed the potential 
of human placenta to metabolize 
polycyclic aromatic hydrocarbon, 
benzo(a)pyrene (BP) by indicating 
BP-diolepoxide-DNA adducts from 
perfused placental cotyledon. In ad-
dition, by analyzing a large series of 
perfusions, it was found that trans-
placental transfer may be weakened 
towards the end of pregnancy.
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ABSTRACT
The fetus is exposed to many chemicals via the placenta during pregnancy. Fetal exposure
has been demonstrated by analyzing the chemicals in cord blood, fetal hair and meconium.
Moreover, it is known that fetal exposure to toxic compounds can lead to malformations
and neurodevelopmental disorders. It is challenging to study human fetal exposure to
known harmful compounds because pregnant mothers cannot be deliberately exposed to
these chemicals. Extrapolation of animal data to humans is not very reliable because there
are more between-species differences in placental structure and functions than in any other
organ. In the human placental perfusion model, the tissue structure is retained, and thus
placental toxicokinetics including transplacental transfer and related mechanisms e.g.
efflux-transporters and xenobiotic metabolizing enzymes can be studied.
In this study, human placental perfusion was used to determine placental toxicokinetics
of several chemical carcinogens i.e. benzo(a)pyrene (BP), ethanol, nicotine, 2-amino-1-
methyl-6-phenyl-imidazo(4,5-b)pyridine (PhIP), and N-nitrosodimethylamine (NDMA). All
of these compounds crossed the placenta, although there were differences in their transfer
rates. It was found that inhibitions of ABC-efflux transporters did not affect transplacental
transfer  of  BP  or  PhIP.   BP  was  the  most  problematic  compound  in  placental  perfusion
because of the poor recovery probably due to binding of BP to the tubing of the perfusion
equipment. The metabolic capacity of human placenta in placental perfusion was
confirmed by detecting the BPDE-DNA adducts from perfused placental cotyledon. It was
also observed that ethanol did not affect acutely (i.e 4 hours) the transplacental transfer of
the studied chemicals.
The accumulated perfusion data collected in our perfusion laboratory in Kuopio makes it
possible to undertake correlations between placental and birth related factors and the
success of perfusion. The success of perfusion was defined by a marker which mapped
overlapping of perfused areas in maternal and fetal sides (equilibration of the reference
compound antipyrine between maternal and fetal circulations) and another marker
estimating the integrity of the fetal villous structure (volume loss from fetal to maternal
circulation ǂ 3 ml/h). The negative correlation coefficient detected between placental age
and the transfer of antipyrine revealed that placental transfer may be weakened towards
the end of pregnancy, especially after due date. The way of delivery or the weight of
placenta did not affect the perfusion outcome.
The validation status of human placental perfusion as a toxicity test was evaluated based
on the requirements to complete seven test modules defined by the European Centre for the
Validation of Alternative Methods (ECVAM).
National Library of Medicine Classification: QV 38, QZ 202, WQ 210.5, WQ 212
Medical  Subject  Headings:  Placenta;  Perfusion;  Maternal-Fetal  Exchange;  Fetus;  Environmental  Exposure;
Toxicokinetics; DNA Adducts; Carcinogens; Benzo(a)pyrene; Ethanol; Nicotine; Imidazoles; Pyridines;
Dimethylnitrosamine
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TIIVISTELMÄ
Sikiö altistuu raskauden aikana istukan kautta monille kemikaaleille, mikä on osoitettu
analysoimalla kemikaaleja napaverestä, sikiön hiuksista sekä mekoniumista. Lisäksi
tiedetään, että kohdussa altistuminen toksisille aineille voi johtaa epämuodostumiin ja
neurologisiin kehityshäiriöihin. Sikiön altistumisen tutkiminen on haastavaa, koska
raskaana olevia naisia ei voi altistaa tarkoituksellisesti haitallisille aineille. Myöskään
eläinkokeilla saadun tiedon soveltaminen ihmisiin ei ole kovin luotettavaa, koska istukan
rakenne  ja  toiminta  eroaa  eri  eläinlajien  välillä  enemmän  kuin  minkään  muun  elimen.
Ihmisen istukkaperfuusiossa kudosrakenne pystytään säilyttämään. Tässä mallissa voidaan
tutkia istukan toksikokinetiikkaa mukaan lukien istukan läpi kulkeutuminen ja siihen
liittyvät mekanismit kuten efflux-kuljetusproteiinit tai vieraainemetabolian entsyymit.
Tässä työssä ihmisen istukkaperfuusiota käytettiin kemiallisten karsinogeenien,
benzo(a)pyreenin (BP), etanolin, nikotiinin, PhIP:n ja N-nitrosodimetyyliamiinin (NDMA)
toksikokinetiikan selvittämiseen istukassa. Kaikki tutkitut yhdisteet kulkeutuivat istukan
läpi, vaikka kulkeutumisnopeudessa olikin eroja. ABC-efflux kuljetusproteiinien toiminnan
estolla ei ollut vaikutusta BP:n tai PhIP:n istukan läpi kulkeutumiseen. BP oli yhdisteistä
ongelmallisin, koska sen saanto istukkaperfuusiosta oli huono. Todennäköisin selitys tälle
on BP:n sitoutuminen perfuusiolaitteiston letkuihin. Istukan kyky vierasainemetaboliaan
todettiin osoittamalla bentso(a)pyreenidioliepoksidin DNA-sitoutumistuotteita
perfusoidusta istukkalohkosta. Oli myös selvää, ettei etanoli akuutisti 4 tunnin aikana
vaikuta tutkittujen aineiden istukan läpi kulkeutumiseen.
Laboratoriossamme Kuopiossa kerättyjen tietojen ansiosta oli mahdollista selvittää
istukkaan ja synnytykseen liittyvien tekijöiden vaikutusta perfuusioiden onnistumiseen.
Onnistunut perfuusio määriteltiin osoittamalla sikiön ja äidin puoleisten perfuusioalueiden
päällekkäisyys (referenssiaine antipyriinin tasapainottuminen äidin- ja sikiönpuoleisen
kierron välillä) ja sikiön villuspuuston eheys (nestehävikki sikiön puoleisesta kierrosta
äidin puoleiseen kiertoon ǂ 3 ml/h). Negatiivinen korrelaatio istukan iän ja antipyriinin
istukan läpi kulkeutumisen välillä paljasti, että aineiden istukan läpi kulkeutuminen voi
olla heikentynyttä loppuraskaudessa, erityisesti lasketun ajan jälkeen. Sen sijaan
synnytystavalla tai istukan painolla ei ollut vaikutusta perfuusion onnistumiseen.
Ihmisen istukkaperfuusion validoimista toksisuustestiksi arvioitiin vaihtoehtoisten
tutkimusmenetelmien Euroopan keskuksen (ECVAM) määrittelemän seitsemänosaisen
testin vaatimuksiin perustuen.
Luokitus: QV 38, QZ 202, WQ 210.5, WQ 212
Yleinen suomalainen asiasanasto: istukka; läpäisevyys; sikiö; altistuminen; karsinogeenit; toksikologia
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1 Introduction
Tragic examples of the consequenses of fetal chemical exposure have occurred in recent
history. Probably the best known teratogen, thalidomide, caused skeletal malformations in
the offspring of mothers who used it as an anti-emetic sedative and anti-anxiety drug
during pregnancy in the late 1950s and early 1960s (Woollam, 1965). Nowadays, many
more teratogens are known including alcohol and many therapeutic drugs (Etwel et al.,
2014). Furthermore, it is also known that transplacental carcinogenesis can occur also in
humans. The children of mothers who used diethylstilbestrol during pregnancy were born
with various anomalies, some of these children developed cancers that only became
manifest later in life (Rubin, 2007). These tragedies have emphasized that exposure to
chemicals during pregnancy may harm the fetus. In addition, fetal exposure may impair the
quality of life of the child in other ways. One good example is the cognitive problems
caused by alcohol drinking during pregnancy. Other possible consequences associated with
fetal exposure to different xenobiotics include spontaneous abortions, neurocognitive
developmental delays, and adult onset diseases that have their origins during the fetal
period (Vähäkangas, 2011).
Thus, pregnant mothers carry a huge responsibility to control the kinds of compounds to
which  they  expose  themselves  and  their  fetus  during  pregnancy.  In  many  cases,  mothers
knowingly  expose  their  babies  to  toxic  agents  e.g.  to  ethanol  and  to  the  thousands  of
chemicals present in cigarette smoke. In the US, more than 10% of pregnant women drink
alcohol during pregnancy (Disney et al., 2008; Floyd and Sidhu, 2004). A similar trend was
clearly visible in a query of Finnish women, where 6% admitted their dependency on illegal
drugs or/and alcohol during pregnancy (Pajulo et al., 2001). Even today, smoking is all too
common among pregnant women. In Finland, in 2013, 16% of all pregnant mothers smoked
in early pregnancy, which is the highest proportion of all the Nordic countries. Only 43.8%
of these smoking mothers-to-be gave up smoking during the first trimester (THL, 2014).
However in many cases, fetal exposure has not been caused on purpose. For instance,
women may drink alcohol during early pregnancy before they are even aware that they are
pregnant (Floyd et al., 1999).
In contrast to the widely held belief, human placenta is a poor barrier against
xenobiotics. It is an essential organ for the fetus because it is the fetus´s only gateway to the
world outside the uterus. Fetal exposure has been demonstrated for many compounds by
measuring different chemicals and their metabolites from fetal blood, hair or meconium
(Barr et al., 2007). Most compounds pass the placenta by passive diffusion although there
are also other mechanisms (Syme et al., 2004). Transplacental transfer is usually determined
by the physico-chemical properties of the transferring compounds. Nevertheless, the extent
of fetal exposure can also be affected by the ABC efflux-transporters and by the presence of
metabolizing enzymes found in human placenta (e.g. reviewed by Prouillac and Lecoeur,
2010 and Vähäkangas et al., 2011). The expression of ABC-transporters and metabolic
enzymes in the placenta changes with gestational age. There are also interindividual
differences in the expression of these enzymes mainly because of genetic polymorphisms,
but it can also be altered by different diseases or xenobiotics.
It is difficult to study fetal exposure to toxic chemicals because it is ethically impossible
to expose mothers to harmful chemicals on purpose (Vähäkangas et al., 2011). Human
placental  perfusion provides  an opportunity  to  study transfer  and related mechanisms of
different chemicals in the relevant and structurally intact human tissue (Myllynen and
Vähäkangas, 2013). The differences between species in the anatomy and physiology of
placenta are greater than in any other organ but by utilizing the human placenta there is no
need of extrapolation from animal data to humans (Leiser and Kaufmann, 1994). Unless
2there is some medical reason, in Finland the human placenta is disposed of after birth.
Therefore, it is ethically acceptable to use placenta in research if mothers consent to its
utilization. If it is to be used in perfusion studies, the human placenta has to be collected
immediately after birth and kept alive and metabolically active in the laboratory. There are
several advantages associated with this method; primarily the human placenta can be used
after birth without interfering with the health of mother or fetus. The method using isolated
placental tissue provides direct information of placental functions without disturbing
inputs from other tissues. The most significant disadvantage is that the term placenta,
which  is  most  commonly  used,  represents  only  the  placenta  which  is  present  at  the  end
stage of pregnancy. The method is also laborious and the success rate is low. Usually only
one out of every five or more of the placentas delivered from hospital end up in a
successful perfusion experiment (Mathiesen et al., 2010). In order to confirm that perfusion
was successful, different criteria have to be fulfilled to assess placental integrity, viability,
and overlap between the maternal and fetal perfused areas. However, there are no
generally accepted limit values which are used by all research groups perfusing placentas.
It has been reported that transfer data from human placental perfusions correlates well
with the existing in vivo data supporting the validity of the method (Hutson et al., 2011;
Vähäkangas et al., 2011).
In this thesis, the interest was in transplacental transfer and some mechanisms
contributing to transfer of some toxic compounds to which mothers may be exposed during
pregnancy. Human placental perfusion was used as the main research method but the
technique itself was also a target of study. The large amount of accumulated data from
perfusions (more than 100 perfusions) carried out in Kuopio in the same laboratory for over
a decade was used to study the association between placental and birth related factors and
the success of perfusion experiments.
32 Review of Literature
2.1 FETAL EXPOSURE
2.1.1 Significance of the fetal exposure in humans
The fetus is exposed in uterus to many chemicals including therapeutic drugs (Eshkoli et
al., 2011), heavy metals (Caserta et al., 2013), and food carcinogens (Myöhänen and
Vähäkangas, 2011). The types of compounds will depend mainly on the lifestyle of the
mother for example, if the mother has to take some medications during her pregnancy. The
route for fetal exposure is via the mother and for most of the pregnancy that will mean
transfer via the placenta. Fetal health can be threatened not only by direct toxic effects on
fetus but also via placental toxicity (Myllynen et al., 2005). In addition to genetic
susceptibilities inherent in the growing fetus, the consequences to the fetus can depend on
the time frame of exposure, toxicity of the agent, the type of exposure (acute or chronic) and
amount of the exposure. The fetal exposure and possible fetal consequences of the
compounds studied in this thesis (benzo(a)pyrene and nicotine, both of which are found in
cigarettes, ethanol, the food carcinogens PhIP and NDMA, and buprenorphine, which is
used in opioid replacement therapy in opiate dependent individuals during pregnancy) are
summarized in Table 1.
Table 1. Summary of fetal exposure and known fetal consequences in humans.
Compound Nature of
compound
Transplacental
transfer shown
Fetal consequences
ex vivo in vivo
Benzo(a)pyrene Environmental
carcinogen; food
carcinogen
Yes1 Yes2,3,4 Impaired fetal growth5, atypical
mental development at the age of 3
by PAH-exposure6
NDMA Food carcinogen Yes7 No ND
PhIP Food carcinogen Yes8 No ND
Buprenorphine Medical drug;
substance of
abuse
Yes9,10 Yes11 Possible premature birth12,
withdrawal symptoms11, decreased
head circumference11
THC Substance of
abuse
No Yes13 Slight behavioral and cognitive
developmental changes later in life14
Ethanol Recreational drug Yes15 Yes16 Fetal alcohol spectrum disorders
(FASD) e.g. fetal alcohol syndrome
(FAS) and teratogenesis17,18
Nicotine Recreational drug Yes19 Yes20 spontaneous abortions, fetal growth
restriction, and sudden infant death
syndrome by cigarette smoking21
ex vivo: human placental perfusion; NDMA=N-nitrosodimethylamine; PhIP=2-amino-1-methyl-6-phenyl-
imidazo(4,5-b)pyridine; THC=Ʃ9-tetrahydrocannabinol; ND=not defined
References: 1Mathiesen et al., 2009; 2Mumford et al., 1993; 3Arnould et al., 1997; 4Topinka et al., 2009;
5Duarte-Salles et al., 2012; 6Perera et al., 2006; 7Annola et al., 2009; 8Myllynen et al., 2008; 9Nanovskaya
et al., 2002; 10Nanovskaya et al.,2009; 11Kacinko et al., 2008; 12Lejeune et al., 2006; 13Blackard and
Tennes, 1984; 14Huizink, 2014; 15 Karl et al., 1988; 16Idänpään-Heikkilä et al., 1972; 17Jones et al., 1973;
18Pruett et al., 2013; 19Pastrakuljic et al., 1998; 20Luck and Nau, 1984; 21Bruin et al., 2010
4Fetal exposure to harmful agents can manifest in many different ways. During
pregnancy, many therapeutic drugs may cause intrauterine growth retardation,
prematurity, and stillbirth (Etwel et al., 2014). Teratogenic compounds can cause congenital
aberrations including clearly visible effects such as structural malformations but also
functional  deficiencies  in  different  internal  organs.  There  is  a  broad  spectrum  of  well-
known human teratogens such as infectious agents, many therapeutic drugs, and alcohol
(reviewed by Rasmussen, 2012). Ethanol is a well-known teratogen causing fetal alcohol
spectrum disorders (FASD) including the well-characterized fetal alcohol syndrome (FAS)
in the newborn. Moreover, in animals transplacental carcinogenesis is a recognized
phenomenon (reviewed in Anderson et al., 2000) and this phenomenon can also possibly
occur  in  humans,  although  there  is  only  one  chemical  proven  so  far  to  exert  this  type  of
effect, diethylstilbestrol. This drug was used by millions of pregnant women to prevent
miscarriages and other disorders (Veurink et al. 2005). However, subsequently fetal
exposure was found to be associated with cancers and anomalies of reproductive organs in
both sexes (Palmer et al. 2009).
Fetal exposure to different compounds can be detected by analyzing fetal blood,
meconium, and hair (Barr et al., 2007; Etwel et al., 2014). Chronic exposure to
environmental chemicals, ethanol, and other substances of abuse can be studied by
examining hair and meconium. For instance, if there is a suspicion that mother has
consumed large amounts of alcohol during pregnancy, this can be confirmed by measuring
the levels of ethyl glucuronide (EtG) and nonoxidative metabolites of ethanol, fatty acid
ethyl esters (FAEEs) from fetal hair (Pragst and Yegles, 2008).
In recent years, it has been speculated that many diseases have their origins during the
fetal period (Barker and Thornburg, 2013). Lately, there has been increased interest in
clarifying the role of epigenetic changes related to diseases of fetal origin (Hou et al., 2012).
Epigenetic changes include DNA methylation, histone modifications, and microRNAs
(Maccani and Marsit, 2009).  Many environmental compounds can cause epigenetic
changes, and these types of changes have been associated with the susceptibility towards
many diseases (Hou et al., 2012). Furthemore, the epigenetic changes occurring in the fetal
period may be permanent and thus the sensitivity to different pathological states including
cancer may be present for the individual´s entire lifespan (Vähäkangas, 2011).
2.1.2 Food carcinogens
Benzo(a)pyrene
Benzo(a)pyrene (BP), a carcinogenic PAH (polycyclic aromatic hydrocarbon) compound is
ubiquitous in the environment. BP is produced as a consequence of incomplete combustion
of organic material. Humans are exposed to BP mostly via cigarette smoking, city air, and
grilled and smoked food but also occupationally if employed in certain industries
(Lindstedt and Sollenberg, 1982; Pyy et al., 1997; Phillips, 1999). IARC has classified BP as
class 1, carcinogenic to humans (2010). The carcinogenicity in animals was proven already
much  earlier  (IARC  1973).  In  animals,  BP  has  been  shown  also  to  be  a  transplacental
carcinogen causing tumors later in life after fetal exposure of offspring (Lu et al., 1986a).  BP
is an indirect carcinogen and it requires metabolic activation to the actual carcinogenic
agent, benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) (Pelkonen and Vähäkangas,
1980; Hruszkewycz et al., 1992). This metabolite can bind to DNA and form DNA-adducts.
In experimental studies PAH derived DNA adducts usually form at guanine residues near
to methylated cytosines (Denissenko et al., 1996; Chen et al., 1998).
BP is metabolized by both functionalization and conjugation enzymes into a wide variety
of metabolites (Miller and Ramos, 2001). The primary metabolites include phenols,
epoxides, dihydrodiols, and quinones (IARC 2010). The major enzymes involved in the
formation of most carcinogenic diols and diolepoxides of BP are CYP1A1, CYP1A2, and
CYP1B1 (Shimada and Fujii-Kuriyama, 2004; Shimada, 2006). These CYP enzymes are
inducible by many PAHs including BP (Ma and Lu, 2007). The mechanism in the induction
5is binding of PAHs to the aryl hydrocarbon-receptor (AhR) nuclear complex, which induces
the transcription of the genes of some CYPs and phase II enzymes (Shimada, 2006). BP has
been shown to activate AhR moderately and consequently to induce CYP1A1 (Machala et
al., 2001; Spink et al., 2008).
The extent  of  fetal  exposure  to  BP depends on the  lifestyle  of  the  mother.  BPDE-DNA-
adducts have been found both in the placentas of smoking mothers (Manchester et al. 1988)
and also in cord blood confirming the transplacental transfer of BP (Mumford et al.,  1993;
Arnould et al., 1997; Topinka et al., 2009) (Table 1). Furthermore, detectable concentrations
of adducts in cord blood have been associated with increased global methylation levels
(Herbstman et al., 2012).  The amounts of BP-DNA adducts in neonatal buccal cell samples
have been shown to correlate well with the levels of maternal self-reported smoking
(Stephan-Blanchard et al., 2011). It has also been proven that CYP1A1 has a major role in
the placental metabolism of BP (Vähäkangas et al., 1989; Lagueux et al., 1999; Stejskalova
and Pavek, 2011).
Maternal intake of PAHs and elevated CYP1A1 activity through activated AhR have
been associated with reduced fetal growth (Stejskalova and Pavek, 2011). In two recent
studies conducted by Duarte-Salles et al. (2012; 2013) the estimated dietary intake of BP was
linked to impaired fetal growth, whereas increased intake of vitamin C led to a reduction of
adverse effects caused by BP. Impaired fetal growth was noted especially in mothers with a
specific  polymorphism  in  the  gene  for  glutathione  S-transferase  P1  (GSTP1),  an  enzyme
which can deactivate the diolepoxide metabolite of BP (Duarte-Salles et al., 2012). In a
recent study, Pedersen et al. (2013) suggested that the cord blood adduct level was
negatively associated with birth weight and that the maternal fruit and vegetable
consumption may exert a protective role. Similar data was also provided by Guo et al.
(2012) from Guiyu, China. The extent of prenatal exposure to PAHs including BP correlated
well with adverse effects on neonatal health and furthermore, the concentrations of PAHs
were greater in umbilical cord than in maternal blood (Guo et al., 2012). Moreover, in
epidemiological studies prenatal exposure to PAHs has been associated with atypical
mental development at the age of 3 (Perera et al., 2006) and also with a lower intelligence
score a couple of years later (Edwards et al., 2010). At the age of 6-7 years, high prenatal
PAH exposure has been shown to correlate with psychiatric symptoms such as anxiety,
depression, and attention problems (Perera et al., 2012).
In rats, intrauterine exposure to BP has been associated with functional deficits in
cardiovascular development that may become expressed later in life as cardiovascular
dysfunction (Jules et al., 2012).
NDMA
NDMA (N-nitrosodimethylamine) belongs to a large family of N-nitroso compounds. The
exposure can occur by consumption of preformed NDMA in the diet, for instance from
cured  meat  or  fish,  bacon  or  beer.  NDMA  can  also  be  formed  endogenously  when  food
containing nitrite or nitrogen oxide is ingested together with a nitrosable substrate such as a
secondary amine (Lijinsky, 1999; Wogan and Tannenbaum, 1975). The nitrosation reaction
can be prevented by antioxidants such as vitamin C, which scavenges nitrites by converting
them to nitric oxide, if vitamin C-containing food is ingested at the same time (Mirvish et
al., 1972; Mirvish, 1996). NDMA metabolism is catalyzed mainly by CYP2E1 (for a review,
see e.g. Yang et al., 1991) but it has been speculated that CYP2A6 may also be involved
(Camus et al., 1993; Kushida et al., 2000). The active metabolite of NDMA is an alkylating
methyl diazonium ion causing both O6-methylguanine and N7 –methylguanine adducts;
these are not specific for NDMA but also can be produced by other methylating agents
(Pegg, 1980; Kyrtopoulos, 1998). Of these adducts, O6-methylguanine is thought more
likely to be responsible for the mutagenicity and carcinogenicity (Loveless, 1969; Goth and
Rajewsky, 1974).
6NDMA is a transplacental carcinogen in many animal species (Anderson et al. 1989,
Beebe et al. 1993).  In patas monkeys, O6-methylguanine adducts were found in placenta
and fetal liver after exposing pregnant monkeys to NDMA (Chhabra et al., 1995). IARC
classifies NDMA only as a probable human carcinogen (category 2A) (IARC 1978).
However, dietary N-nitrosamines have been especially associated with esophageal and
other gastrointestinal cancers (Lu et al., 1986b; Chikan et al., 2012). Similar amounts of O6-
methylguanine  adducts  have  been  found  in  maternal  and  cord  blood  leukocyte  DNA,
evidence that there is transplacental transfer of methylating agents also in humans
(Georgiadis et al., 2000). In human placental perfusion studies NDMA has readily crossed
the placenta, most likely by passive diffusion (Annola et al., 2009) (Table 1). No indication
for  any  interaction  of  NDMA  with  efflux  transporters  has  been  observed  in  Caco-2  and
MDCKII-MDR1 cells. In fact, when the kinetic data of various xenobiotics from human
placental perfusion studies were compared, it was noted that NDMA passed through
placenta better than the other studied compounds (Mose et al., 2012).
PhIP
PhIP (2-amino-1-methyl-6-phenyl-imidazo(4,5-b)pyridine) is the most common heterocyclic
aromatic amine (HAA) which is formed when protein rich food is cooked for a long time at
high temperatures (Felton et al., 2004). The reaction is called the Maillard reaction, and it
requires the presence of creatine, sugars and amino acids such as is found in raw and
protein rich meat (Skog et al., 1998; Knize and Felton, 2005). HAAs are a group of
carcinogens with significant genotoxic potency that may be involved in the etiology of
human cancer development (Felton and Knize, 1991; Sugimura, 1997). The amount of PhIP
in some meats is about 100-fold higher than the amount of the more potent mutagenic
HAAs 2-amino-3-methylimidazo[4,5-f]-quinoline (IQ) and 2-amino-3,8-
dimethylimidazo[4,5-f]quinoxaline (MeIQx) (Stavric, 1994).
The extent of PhIP exposure depends on the amount and type of meat ingested, cooking
method, time and temperature, and how frequently meat is consumed (Augustsson et al.,
1997). The amount of PhIP can be reduced by pre-cooking in a microwave oven, frying at a
lower temperature and turning meat more often during cooking (Busquets et al., 2008).
Interestingly, some experiments conducted in rodents have indicated that some food
components can reduce both the carcinogenicity and the mutagenicity caused by
heterocyclic amines (Schwab et al., 2000; Felton et al., 2004). These types of protective
compounds include fibers, lactic acid bacteria, chlorophyllin, resveratrol, and omega-3 fatty
acids. In addition, some flavonoids, especially apigenin, can prevent the mutagenic activity
of PhIP (Felton et al., 2004). The mechanisms behind the protective role of these compounds
include direct binding, inhibition of the function of the metabolic enzymes that activate
carcinogens,  promotion  of  DNA  repair  processes  and  induction  of  detoxifying  enzymes
(Schwab et al., 2000).
PhIP is a procarcinogen, which needs to be metabolized to a carcinogenic metabolite (N-
OH-PhIP) (Holme et al., 1989) by cytochrome P450 enzymes, especially via CYP1A2,
CYP1A1 and CYP1B1 (Crofts et al., 1998).  According to Han et al. (2008) the role of CYP1B1
may be noteworthy because of interindividual differences in the expression of functional
CYP1B1 in extrahepatic tissues. The carcinogenicity of N-OH-PhIP correlates positively
with the amount of meat consumed. The most common types of cancer associated with
PhIP  are  breast,  colon,  stomach,  and  esophagus  cancers.  Transplacental  exposure  to  PhIP
has been associated with an increased risk of mammary, colon and prostate carcinomas in
rats (Ito et al., 1991; Hasegawa et al., 1995; Shirai et al., 1997). The International Agency for
Research on Cancer (IARC, 1993) has classified PhIP as possibly carcinogenic to humans
(group 2B). Since the classification, epidemiological studies have revealed an association
between the exposure to HAAs, especially PhIP exposure, and an increased risk of breast
cancer (Zheng et al., 1998; Sinha et al., 2000). Fetal exposure to PhIP is somewhat restricted
7by the presence of BCRP in human placenta according to human placental perfusion
studies (Myllynen et al., 2008) (Table 1).
2.1.3 Illegal drugs
Buprenorphine
Buprenorphine  (BUP)  is  used  in  the  treatment  of  moderate  to  severe  pain  and  in  opioid
replacement therapy in pregnant opiate dependent patients, but it is also a widely misused
street drug (Robinson, 2002; Lofwall and Walsh, 2014). During pregnancy, it is considered
as a safer choice than methadone because of its long half-life, and because it does not
produce such intense withdrawal symptoms in the newborn, and also hospitalization time
after birth is shorter with BUP than with methadone (Johnson et al., 2003; Jones et al., 2005).
Lejeune et al. (2006) have reported that there is a slightly increased possibility of premature
birth (weeks of gestation <37) with the usage of BUP. The effects of BUP on fetal
development and potential later effects have been recently reviewed (Konijnenberg and
Melinder, 2011; Jones et al., 2012). Currently, it is not clear whether or not BUP causes
adverse developmental outcomes.
BUP is metabolized to its primary and active metabolite norbuprenorphine (nBUP) in
liver, mainly by the CYP3A4 enzyme (Iribarne et al., 1997; Kobayashi et al., 1998). The
plasma concentration of nBUP at steady state is equal to or higher than that of the parent
compound (Kuhlman et al., 1998).
In  placental  perfusion  studies,  BUP  has  been  found  to  pass  through  human  placenta
although rather slowly (Nanovskaya et al., 2002) (Table 1). Human plasma protein levels
influence placental transfer of BUP (Nanovskaya et al., 2009). When physiological
concentrations  of  human  serum  albumin  (HSA)  and  ΅-acid  glycoprotein  (AAG)  were
added, the BUP concentration increased both in maternal and in fetal circuits and decreased
the amount retained by the tissue, even though feto-maternal ratio remained the same.
Moreover, Nanovskaya and coworkers (2009) also found that BUP was bound mainly to
AAG. In addition, the age of the human placenta had no effect on the transfer of BUP when
this was examined in two different age groups of placentas (30-34 weeks and 39-42 weeks)
(Fokina et al., 2011). Metabolism of BUP also occurs in human placenta, where BUP is
metabolized to nBUP mainly by CYP19A1 (Deshmukh et al., 2003).
The transporter proteins can represent one potential site for interactions between
chemical compounds. Tournier et al. (2010) have shown that BUP affects the function of the
ABC efflux transporter, ABCG2/BCRP, even though it is not transferred by the transporter.
The  function  of  ABCG2  was  inhibited  by  BUP  in  bidirectional  transport  studies  across
monolayers of hBCRP-transfected MDCKII cells (Tournier et al., 2010). According to
Hassan et al. (2009), BUP is not a substrate of human ABCB1/P-gp. However, in mice,
ABCB1 has been shown to possess a key role to restrict the transfer of nBUP through the
blood-brain barrier (Alhaddad et al., 2012; Brown et al., 2012).
THC
Cannabis  is  the  most  common  illegal  drug  in  the  world  (United  Nations  Office  of  Drugs
and Crime, World drug report 2013). However, cannabis and cannabinoid preparations
have also been used therapeutically e.g. to alleviate side effects of chemotherapy or to
relieve spasticity caused by multiple sclerosis (Grotenhermen and Müller-Vahl, 2012).
Additionally, there are claims that cannabinoids possess promising antitumor effects
against certain types of cancers, such as glioma, lung carcinoma and breast cancer (Velasco
et al., 2012).
THC (̇9-tetrahydrocannabinol) is the most potent of the many psychoactive compounds
present in cannabis (Gaoni and Mechoulam, 1971). THC binds and activates both CB1 and
CB2 cannabinoid receptors (Felder and Glass, 1998). The THC content is dependent on the
8type of cannabis e.g. marijuana contains approximately 6% THC, whereas hashish contains
more than 20% THC (Mehmedic et al., 2010). The concentrations of THC in confiscated
marijuana have increased significantly in recent years, which has been thought to be the
main reason for increased abuse and dependence associated with recreational cannabis use
(Compton et al., 2004; Mehmedic et al., 2010).
The primary metabolite of THC is the therapeutically active 11-hydroxy-THC, which is
formed by hydroxylation catalyzed by CYP2C9 (Watanabe et al., 1995; Bland et al., 2005).
The metabolite is then further oxidized through one intermediate to 11-nor-9-carboxy THC
(THC-COOH) in a reaction catalyzed by aldehyde oxygenase (Wall et al., 1983; Watanabe et
al., 1995).  Subsequently, the ultimate metabolite is excreted in urine where it can be
detected for up to four days after smoking one marijuana cigarette and for as long as weeks
to months after chronic use (Verstraete, 2004). There is a possibility of significant
interactions with many other structures in addition to the CB1 and CB2 receptors. There are
in vitro studies, where THC increased the rate of phenytoin metabolism by CYP2C9 in
human liver microsomes (Bland et al., 2005). The potential interaction with THC could
occur also through ABC transporter proteins. It has been reported that THC slightly
inhibited the function of BCRP in two different ABCG2 transfected cell lines (MEF3.8/Bcrp1
A2 and BCRP-MDCKII) but the protein expression of BCRP was not affected (Holland et
al., 2007; Tournier et al., 2010). Moreover, Spiro et al. (2012) have shown that P-gp and
BCRP restricted the transfer of THC to the brain, at least in mice.
In an epidemiological study published by Mueller et al. (1990), women who admitted to
smoking marijuana had an increased risk  of  infertility.  THC has  been shown to  cross  the
term human placenta (Blackard and Tennes, 1984) (Table 1). Detectable concentrations of
THC and its main metabolite (11-hydroxy-THC) were measured from six mothers and from
three of their infants in samples taken during delivery. The concentrations in maternal
blood were from 2.5 to 6 times greater than in cord blood. Potential harmful effects of
prenatal cannabis exposure on fetal developmental outcome have been reviewed recently
(Huizink, 2014). There are many inconsistencies in the data but slight behavioral and
cognitive developmental changes in the offspring have been detected. Moreover, frequent
use of cannabis during pregnancy has been associated with a marginal but statistically
significant decrease in birth weight (English et al., 1997).
2.1.4 Ethanol and nicotine
Ethanol
Ethanol is the most widely used recreational drug in the world. In human liver, ethanol is
metabolized to acetaldehyde mainly by alcohol dehydrogenase (ADH), and then
acetaldehyde is broken down to acetic acid by aldehyde dehydrogenase (ALDH) (Zelner
and Koren, 2013).  Acetaldehyde is a toxic metabolite that causes many of the problems
associated with ethanol ingestion. Alcohol drinking has been classified as carcinogenic to
humans (Group 1)  by the  International  Agency for  Research on Cancer  (IARC 1988).  The
sites  of  malignant  tumors  caused  by  alcohol  drinking  are  oral  cavity,  pharynx,  larynx,
esophagus and liver. One possible mechanism for the carcinogenicity of alcoholic beverages
may be the ability of acetaldehyde to bind DNA and form different types of DNA adducts
(Vaca et al., 1995; Poschl and Seitz, 2004). Ethanol is a good solvent and in this way it could
enhance  the  transfer  of  carcinogenic  compounds  through  the  mucosa  (Brennan  and
Boffetta,  2004).  This  theory  is  supported  by  studies  where  ethanol  has  been  shown  to
reduce membrane integrity (Frischknecht and Frink, 2006; Terama et al., 2008). Patra and
coworkers (2006) have also found that biological membranes became more fluid and
permeable in the presence of ethanol.
Alcohol drinking during pregnancy increases the risk of spontaneous abortions,
placental abruptions, and prenatal mortality (Kline et al., 1980; Pruett et al., 2013). Ethanol
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direct fetotoxic effects of ethanol or acetaldehyde or by indirect effects via ethanol induced
placental malfunction or weakened fetal nutrition (Fisher and Karl, 1988; Bosco and Diaz,
2012). The most feared consequence of chronic alcohol consumption during pregnancy is
fetal alcohol syndrome (FAS) which was first described in 1973 (Jones et al., 1973; Jones and
Smith, 1973), although it has been known for hundreds of years that ethanol causes harm to
fetus (for a review, see e.g. Calhoun and Warren, 2007). FAS is characterized by craniofacial
malformations, intrauterine growth retardation (IUGR), cardiac septal defects, and mental
retardation. A more comprehensive term for the harmful effects of ethanol on fetus is fetal
alcohol spectrum disorder (FASD), which includes FAS but also other alcohol-related birth
defects with not so visible damage such as neuropsychological deficits manifesting later in
life (Riley and McGee, 2005; Riley et al., 2011; Pruett et al., 2013). The prevalence of FASD in
the US has been estimated to be surprisingly high: 2-5% in younger school children (May et
al., 2009). Previously, it has been estimated that in Finland the prevalence of FASD would
be about 0.9% and from these children about 12% fulfil the criteria of FAS (Halmesmäki
and Autti-Rämö, 2005).
It has been shown in vivo that ethanol readily goes through term human placenta, and
the elimination of ethanol by fetus is twice as slow as by mother (Idänpään-Heikkilä et al.,
1972) (Table 1). Because of the limited fetal ethanol metabolism, the elimination of ethanol
occurs mainly in the maternal compartment (reviewed by Heller and Burd, 2014). Ingested
ethanol has been measured from amnion fluid where the maximum concentration was half
that present in the maternal venous concentration but the elimination from amnion fluid
was twice as slow as from maternal blood (Brien et al., 1983). The rate-limiting mechanism
for the elimination of ethanol from amniotic fluid is reabsorption, which occurs after 20
weeks of gestation when due to skin keratinization, reabsorption no longer occurs through
the fetal skin, but by fetal swallowing and via intra-membranous pathways (Underwood et
al., 2005; Beall et al., 2007). In the study of Brien et al. (1983), acetaldehyde could be
measured in venous blood from 4 out of 6 mothers but in only one of these mothers could
acetaldehyde be detected from amniotic fluid. In this mother, the concentration of
acetaldehyde was greater in amniotic fluid than in maternal blood.
The perfused human placental cotyledon is able to metabolize ethanol to acetaldehyde,
which can be detected in fetal circulation (Karl et al. 1988). The data about mechanisms
behind this phenomenon is controversial. One isoform of ADH has been found in placenta
but at a very modest level, less than 0.002% of the amount of ADH in liver (Pares et al.,
1984). However, Andersson et al. (1989) were not able to detect ADH at all from 13
placentas  of  mothers  who  were  chronic  alcohol  abusers  during  pregnancy  or  from  16
control placentas. Thus, it is feasible to think that metabolism of ethanol by ADH is not
very significant in human placenta.
One possible metabolic pathway in ethanol metabolism could be the oxidative CYP2E1
in placenta. This is an enzyme the levels of which can be induced in human liver by alcohol
and in some pathological situations such as obesity and diabetes (Neafsey et al., 2009).
CYP2E1 has been detected in term placentas at the mRNA level (Hakkola et al. 1996). In the
literature, there is no clarity about whether or not there is CYP2E1 enzymatic activity in
placenta. It is clear that in normal pregnancies functional CYP2E1 cannot be found in
human placenta (McRobie et al., 1998; Collier et al., 2002; Czekaj et al., 2005). There is only
one study where CYP2E1 was suggested to be found from placentas of mothers who had
consumed alcohol during pregnancy, a result which the authors interpreted as indicating
that enzyme activity could be induced by ethanol also in placenta (Rasheed et al., 1997).
However, they did not study whether the enzyme was actually functional.
The harmful effects of ethanol exposure on placentation, placental growth and function
have been reviewed by Burd et al. (2007). For instance, ethanol causes placental
vasoconstriction possibly involving placental adenosine and these vascular changes would
be predicted to be associated with impaired oxygen transport (Acevedo et al., 1997).
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Recently, ethanol has been shown to exert cytotoxic effects in vitro in human trophoblast
cells (JEG-3) (Clave et al., 2014).
There are also indications that fetal exposure to ethanol increases the risk for leukemia in
childhood (Langmuir et al., 2001). In the case-control study of Severson et al. (1993), a
possible connection was noted between alcohol consumption of the mother during
pregnancy and the incidence of acute myeloid leukemia in the offspring before 2 years of
age. In addition, Shu et al. (1996) also found the same connection between ethanol exposure
during pregnancy and leukemia in the children which strengthens the potential association.
Nicotine
Nicotine is only one of the more than 4000 chemicals known to be present in cigarette
smoke  but  it  is  a  very  potent  toxic  and  addictive  compound  (Stolerman  and  Jarvis,  1995;
Hecht, 1999). Cigarette smoking during pregnancy is known to induce many adverse
outcomes such as spontaneous abortion, placental abruption, fetal growth restriction and
sudden infant death syndrome (for a review, see e.g. Bruin et al., 2010). Furthermore, there
seems to be a large amount of postnatal consequences associated with maternal smoking
(for a review, see Cnattingius, 2004). The role of nicotine in many smoking associated
problems in humans is still controversial. Nonetheless, there is convincing data originating
from animal models where prenatal exposure to nicotine has been found to be the main
reason for adverse outcomes or susceptibility to many diseases later in life, such as
hypertension, infertility, obesity, type 2 diabetes, respiratory dysfunction, and
neurobehavioral problems (Beratis et al., 1996; Gao et al., 2005; Holloway et al., 2006;
Campos et al., 2009; Dwyer et al., 2009).
Studies into the possible carcinogenic effect of long-term exposure to nicotine and its
metabolites have recently appeared. There are strong indications that nicotine and its
metabolites both initiate and promote tumor growth, especially in certain types of lung
cancer (Zheng et al., 2007; Catassi et al., 2008; Sun et al., 2009). Nicotine has been shown to
induce pathological angiogenesis already at concentrations achievable by light to moderate
smoking (e.g. for a recent review see Lee and Cooke, 2012). Although in many cell types,
nicotine has been shown to induce cell proliferation (Cucina et al., 2012; Shen et al., 2013;
Zeng et al., 2014), in BeWo cells (placental choriocarcinoma cells) nicotine decreased
proliferation while it also increased the levels of reactive oxygen species and the
endoplasmic reticulum –stress related protein GRP78/BiP (Repo et al., 2013).
Nicotine passes through human placenta and is also excreted into breast milk (Luck and
Nau, 1984; Luck et al., 1985). Nicotine is partly retained by placental tissue, in one study the
mean placental tissue/maternal blood ratio was 2.58 (n=17) at birth (Luck et al., 1985). In the
same study, umbilical vein and amniotic fluid concentrations of nicotine were also higher
than maternal blood concentrations at term, indicating that nicotine had crossed the
placenta although placenta may attempt to act as a temporary storage site.  In the human
placental perfusion study of Pastrakuljic et al. (1998), nicotine was significantly retained by
placental tissue but was later leached out into both circulations.
Nicotine  can  be  broken  down  through  many  different  metabolic  pathways  but  it  is
primarily metabolized to cotinine via CYP2A6 in the liver (Hukkanen et al., 2005; Benowitz
et al., 2009). The half-life of cotinine is 15 to 20 hours and the concentration of the
metabolite in serum is 10 times higher than that of nicotine (Lambers and Clark, 1996).
Thus, cotinine is used as a biomarker of smoking rather than nicotine. The cotinine
concentration has been shown to remain at the same level or lower in the fetal serum than
in the corresponding maternal serum levels (Luck et al., 1985; Jauniaux and Gulbis, 2001).
In early pregnancy (7-17 weeks) there is indication that cotinine may accumulate within
fetal compartments (Jauniaux et al., 1999).
Although the long-term effects of nicotine are not known, nicotine replacement therapy
(NRT) during pregnancy has been recommended for those mothers who intend to continue
smoking  during  pregnancy  (Glynn  et  al.,  2009).  This  is  based  on  the  fact  that  NRT  is
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associated with a decreased risk for spontaneous abortions and low birth weight when
compared to continued smoking (Forinash et al., 2010). However, it would naturally be
much better to stop smoking without any replacement; this option should be saved for the
most severely nicotine-dependent cases.
2.2 THE ROLE OF THE PLACENTA IN FETAL EXPOSURE
2.2.1 Human placenta
The structure of human placenta
Placenta is a very complex organ and there are more differences between species in the
anatomy  and  physiology  of  the  human  placenta  than  encountered  in  any  other  organ
(Leiser and Kaufmann, 1994). The placenta is the link between the fetus and the mother,
and  also  the  route  of  fetal  exposure.  The  connection  occurs  as  substances  in  bloodstream
can cross placental barrier, there are no direct nervous connections. The fetus is connected
to placenta via umbilical cord (Figure 1), where one umbilical vein takes oxygen and
nutrients to fetus and two umbilical arteries carry carbon dioxide and other waste products
back to placenta and onwards via different transfer routes to the mother´s circulation.
The development of human placenta begins after the implantation of the blastocyst into
uterine mucosa about 6-7 days after conception (Benirschke et al., 2006). Placental
structures are clearly identifiable at 5-6 weeks of gestation (James et al., 2012), but placental
development continues throughout the whole pregnancy. The term human placenta is a 2-3
cm thick discoidal organ, the diameter of which is about 20-25 cm, and the normal weight
varies between 400-600 g. The type of human placenta is hemochorial, which means that
maternal blood is in direct contact with placental trophoblasts (Benirschke et al., 2006).
The placenta consists of about 15-40 functional units called cotyledons. Cotyledons are
separated by decidual septa and can be recognized from the maternal side of the placenta.
Each of these cotyledons is comprised of a few villous trees and thus there are about 60-70
villous trees in term placenta. The volume of placental villi of total placental volume is
about 45-55% (Kaufmann, 1985). On the maternal side, some villous trees, so-called
anchoring villi, are attached to basal plate. On the fetal side, villous trees end in chorionic
plate (Enders and Blankenship, 1999). In the villous trees, fetal blood circulates either via
arteries and veins in stem villi or via smaller vessels such as capillaries and sinusoids in the
peripheral branches of villous tree (Benirschke et al. 2006). The fetal blood flow in the
placental  vessels  does  not  begin until  3  weeks  after  conception (Enders  and Blankenship,
1999).
Figure 1. Human  placenta.  A)  Cut  placenta  from  fetal  side.  B)  Placenta  from  maternal  side,
where a light area shows a cotyledon perfused from the fetal side.
Villous trees are the main site of fetomaternal transfer of compounds and gases from 11-
12 weeks of pregnancy onwards (Figure 2) (Jaffe et al., 1997; Burton et al., 1999). During the
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first trimester, the development of placenta and embryo/fetus occurs under a low oxygen
environment  and  the  main  routes  for  fetal  access  of  compounds  are  diffusion  through
extracellular fluid or cell-to-cell transport (Benirschke et al., 2006). Maternal blood flow in
intervillous space can be detected at the 6th week of pregnancy, and it increases until the
12th week of pregnancy (Mercé et al., 2009). The flow rate increases from 50 ml/min at 10
weeks to about 600 ml/min at term, which is similar to the blood flow in the adult kidney
(Syme et al., 2004; Aye and Keelan, 2013). Actually, Mercé and coworkers (2009) have
linked a too early onset of intervillous blood flow with an increased risk of miscarriage.
Figure  2.  The  structure  of  fetal  villous  tree.  Photo  of  the  villous  explant  from  term  placenta,
under light microscope. Photo was taken and kindly provided by Jenni Repo.
The maternofetal barrier is a term for the layers that separate maternal and fetal
circulations.  Villous  trees  are  rinsed  by  maternal  blood  from  spiral  arterials.  Thus,  the
barrier is roughly the same as the “cover” of villous tree where the outermost layer is a
continuous multinucleated syncytiotrophoblast from differentiated cytotrophoblasts.
Underneath the syncytiotrophoblast, there are cytotrophoblasts, connective tissue, and a
layer of the endothelium of fetal vessels (Benirschke et al. 2006). The thickness of this
barrier declines with the progression of pregnancy from 50-100 µm in the second month to
only  about  4-5  µm  at  the  end  of  pregnancy.  Cytotrophoblasts  fuse  to  form  the
multinucleated syncytiotrophoblast and their number decreases with the advance of
pregnancy (Gude et al., 2004; Benirschke et al., 2006). At term, only two cell layers separate
the fetal and maternal circulations: the syncytiotrophoblast and endothelial cells of the
vessels of fetal villous tree.
Main functions of human placenta
Briefly, the main functions of human placenta are to maintain pregnancy and support the
normal development of the fetus via hormone production and the transport of gases,
nutrients, and waste products between fetus and mother (e.g. for reviews see Gude et al.,
2004; Donnelly and Campling, 2010). Furthermore, the placenta itself has a low metabolic
capacity and it can restrict the fetal exposure to some xenobiotics, maternal diseases, and
infections. However, the role of the placenta is also essential in the regulation of maternal
physiological systems to adapt to pregnancy including changes in maternal cardiovascular
and metabolic functions (Cross 2006). In late gestation, the fetus will obtain passive
immunity  via  selective  placental  uptake  of  IgG,  which  is  the  only  antibody  to  cross  the
placenta in significant amounts (Palmeira et al., 2012).
The fetus receives all of the oxygen that it needs from the maternal blood. The exchange
of gases occurs readily by passive diffusion. The concentration of fetal hemoglobin (170 g/l)
is higher than the maternal level (120 g/l), and fetal hemoglobin also has a higher affinity
for oxygen (Donnelly and Campling, 2010). Furthermore, fetal hemoglobin has a lower
1 mm
13
affinity for carbon dioxide than maternal hemoglobin, which facilitates carbon dioxide
transfer from fetal circulation to the maternal blood (Gude et al., 2004).
Human placenta produces and secretes many important hormones that influence not
only the success of pregnancy but also the overall welfare of the mother and fetus during
pregnancy: human chorionic gonadotropin (hCG), progesterone, placental growth
hormone, human placental lactogen (hPL), and different cytokines (Table 2). In general, the
secreted  hormones  and  their  amounts  depend  on  the  phase  of  pregnancy.  During  the
organogenesis, main hormonal function in placenta is concentrated on ensuring a good
quality of placentation. Later, when the fetus grows and gains more weight, the hormones
have extensive effects on the maternal metabolism to facilitate the provision of an adequate
energy supply for the fetus (reviewed by Newbern and Freemark, 2011).
The highest levels of human chorionic gonadotropin (hCG), secreted mainly to maternal
circulation, are detectable in early pregnancy, and pregnancy tests are based on the
detection of hCG in urine. This hormone induces the secretion of ovarian progesterone
during the first six weeks of pregnancy and thus supports the pregnancy (Guibourdenche
et  al.,  2009).   In  late  pregnancy,  the  secretion  of  HCG  again  increases;  at  this  time  it  is
involved in the fusion of cytotrophoblasts (reviewed by Malassine and Cronier, 2002).
The mother provides the fetus with all of its vital nutrients through the placenta
including glucose, amino acids, vitamins, minerals, and fatty acids. Furthermore, metabolic
and waste products are transferred in both directions, from mother to fetus and vice versa.
There are specific transporters for many nutrients in placenta, a topic which will be
discussed further in the next chapter. Human placenta can adapt according to fetal
demands of nutrients so that fetal growth continues undisturbed (for recent reviews see e.g.
Fowden and Moore, 2012; Larque et al., 2013). These adaptive processes can be regulated by
altered hormone bioavailability, metabolism, morphology, size of the placenta, or transport
characteristics.
Table 2. Main placental hormones and their main functions during pregnancy. Table is based on
the reviews by Newbern and Freemark (2011), Iliodromiti et al. (2012), and Vähäkangas et al.
(2014).
Placental hormone Main functions during pregnancy
Human chorionic
gonadotropin (hCG)
Promotion of the growth and development of fetus, placenta, and uterus
Supporting the maintenance of the corpus luteum in early pregnancy
Involvement in the fusion of cytotrophoblasts
Human chorionic
somatomammotropin
(HCS)/ Human
placental lactogen
(hPL)
Induction of maternal insulin resistance
Promotion of the growth of maternal tissues
Inhibins Inhibition of follicle-stimulating hormone (FSH) secretion
Inhibition of steroidogenesis and production of hCG
Progesterone Stimulation of maternal food intake
Suppression of cell mediated immunity to prevent rejection of fetus by paternal
antigens
Decrease of prostaglandin production
Placental growth
hormone
Regulation of fetal and placental growth and development
Induction of maternal insulin resistance
Stimulation of maternal metabolism
Relaxin Relaxation of the maternal pelvic ligaments
Contribution to the retention of pregnancy
Leptin Regulation of the fetal and placental growth and development
Maintaining of the energy balance
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2.2.2 The factors affecting transplacental transfer
There  are  many mechanisms by which compounds can cross  the  placenta:  passive  and
facilitated diffusion, pinocytosis, phagocytosis, receptor-mediated uptake, and active
transport but passive diffusion is the most common mechanism (Pacifici and Nottoli, 1995).
Phagocytosis  and  pinosytosis  are  such  slow  events  that  their  role  in  placental  transfer  of
xenobiotics is minor, as also is the contribution of facilitated diffusion (Syme et al., 2004).
The transplacental transfer is affected not only by the physciochemical properties of the
compound but also by numerous placental, maternal, and fetal factors (Reviewed by
Myllynen et al., 2007). The physicochemical properties of the compound including its
lipophilicity, propensity for protein binding, degree of ionization, and molecular weight are
the most important characteristics (Audus, 1999; Syme et al., 2004). Lipid soluble and non-
ionized compounds with a suitably low molecular weight cross the placenta easily. The
limiting value for molecular weight in the literature has been claimed to be 500-600 Da but
the passage of molecules of up to 1000 Da is possible, although restricted (Pacifici and
Nottoli, 1995). However, lipophilicity does not always equate to more complete
maternofetal transfer as discussed below for the case of bupivacaine, which has been shown
to clear quickly from maternal circulation but to accumulate significantly in the placental
tissue (Ala-Kokko et al., 1995; Johnson et al., 1995). It has been proposed that placenta may
act as temporary storage for highly lipophilic compounds and the accumulated compound
may be released into both circulations as was demonstrated to occur with buprenorphine
(Nanovskaya et al., 2002). The degree of ionization is also critical, because only non-ionized
compounds can cross biological membranes. Normally, fetal blood is somewhat more
acidic than maternal blood. During fetal acidosis e.g. during labor, weak bases may
accumulate in the fetal blood. This has been shown with anesthetics and analgesics that can
be provided during labor such as bupivacaine, ropivacaine, 2-chlorocaine, and sufentanil
(Johnson et al., 1996; 1997; 1999). In addition, protein binding of the compound will affect
its transplacental transfer and only free drug fractions can cross biological membranes
(Kwong, 1985; Svensson et al., 1986). The protein concentrations change with increasing
gestational age, but there are also differences in the concentrations between fetal and
maternal blood (Krauer et al., 1984; Larsson et al., 2008).
The physiological properties of placenta e.g. blood flow, increasing surface area with the
advance of pregnancy, protein gradients, the thickness of the maternofetal barrier,
difference in the osmotic pressure between maternal and fetal circulations, and the function
of  different  transporters  and  enzymes  of  xenobiotic  metabolism  all  may  play  significant
roles as well (Bourget et al., 1995; Audus, 1999; Vähäkangas and Myllynen, 2009).
Major changes occur in the maternal and fetal environments with increasing gestational
age and these can lead to changes in the kinetics of different compounds (for reviews see
e.g. Myllynen et al., 2007; Costantine, 2014). Changes in the mother known to take place
during  the  last  trimester  include  increased  plasma  volume  and  renal  blood  flow  with
glomerular filtration rate, and a reduction in the blood albumin concentration. The elevated
progesterone  levels  may  cause  delayed  gastric  emptying  and  reduced  small  intestine
motility (Costantine, 2014).  In addition to lower pH and different protein levels in the fetal
circulation in comparison with the maternal circulation, the fetal clearance may increase the
net transfer of the compounds through the placenta. The fetus may excrete some
compounds to amniotic fluid from where they can be absorbed back to the fetus, but at
least temporarily, the volume of distribution is increased (Rurak et al., 1991). Even though
the fetal metabolic capacity is very restricted compared to the adult, there are indications
that it may affect the concentrations of some compounds. For instance, the fetal elimination
rate of ethanol is about 3-4% of the maternal rate (Heller and Burd, 2014).
Transport of most amino acids, fatty acids, and cholesterol, that are vital for fetal
development, occurs mostly via specific active transport and uptake processes. There are
specific transporters present in human placenta for endogenous substrates but also some
xenobiotics are transported (Ganapathy et al., 1999; Prouillac and Lecoeur, 2010). There are
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transporters from two large transporter families present in human placenta. Solute carrier
transporters include subfamilies that are mainly specialized for the transport of
endogenous  substrates.  There  are  eight  main  groups:  organic  anion-transporting
polypeptides (OATPs), organic anion transporters (OATs), organic cation transporters
(OCTs), amino acid transporters, glucose transporters (GLUT), monoamine transporters,
folate transporters and monocarboxylate transporters. It is clear that the ABC-transporters
play a significant role in the transplacental transfer of some xenobiotics.
2.2.3 ABC-transporters in human placenta
ATP-binding cassette (ABC) transporters are a large protein family that consists of 48
members and 7 subfamilies, A-G (reviewed in Wlcek and Stieger, 2014). Since they have an
active  transport  mechanism,  they  require  ATP  as  energy  for  their  function.  ABC
transporters  are  widely  expressed  in  body  e.g.  in  gut  wall,  liver,  kidneys,  brain,  testicles
and placenta. All of the human ABC proteins are efflux transporters (Wlcek and Stieger,
2014).  They are  involved in  the  transport  of  both endogenous and xenobiotic  compounds
out of cells (Kathawala et al., 2014). Although most of them have been detected at the
mRNA level in human placenta (Nishimura and Naito, 2005) only a few of the actual
proteins have been discovered to be functional in the placenta, including ABCB1/P-gp,
ABCC 1-3 and 5, and ABCG2/BCRP (Vähäkangas and Myllynen, 2009) (Table 3).
Furthermore their expression profiles change with gestational age. Recently Volpicelli and
coworkers (2014) have discovered the presence of ABCB5 in placental cytotrophoblasts,
although the significance and the function of the protein remain unclear.
In the human placenta, the transporters are localized in all membranes of the site of
fetomaternal exchange, including the apical (in contact with maternal blood) and
basolateral membranes of syncytiotrophoblast, and on the endothelial cells of fetal vessels.
Both the type (efflux or influx) and the localization of the transporter determine whether
the transport will be facilitated or restricted.
Table 3. Summary of ABC-efflux transporters in human placenta and their common substrates
(Vähäkangas and Myllynen, 2009; Prouillac and Lecoeur, 2010; Ni and Mao, 2011; Vähäkangas
et al., 2011).
Gene
symbol
Other
commonly used
names
Localization in
placental SCT
or CT
Expression in
endothelium
of fetal
capillaries
Examples of known substrates
and substrate groups
ABCB1 P-glycoprotein
(P-gp), MDR1
SCT/apical - anthracyclines (e.g. doxorubicin),
HIV protease inhibitors,
immunosuppressants, drugs of
abuse, ketoconazole
ABCC1 MRP1 SCT/apical and
basolateral
+ methotrexate, cisplatin,
paclitaxel, glucuronide
conjugates, heavy metal anionic
complexes
ABCC2 MRP2 SCT/apical - methotrexate, cisplatin,
paclitaxel, glucuronide
conjugates, heavy metal anionic
complexes, pravastatin
ABCC3 MRP3 SCT/apical and
basolateral
+ methotrexate, acetaminophen,
glucuronide and sulfate
conjugates
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ABCC5 MRP5 SCT/basolateral + methotrexate, nucleocide
analogues
ABCG2 BCRP, MXR SCT/apical - anthracyclines, mitoxantrone,
estrone sulfates, methotrexate,
zidovudine, pantoprazole, digoxin,
nitrofurantoin
SCT=syncytiotrophoblast, CT=cytotrophoblasts
ABCB1/P-glycoprotein/MDR1
P-glycoprotein (P-gp) was originally found from Chinese hamster ovary cells by Juliano
and Ling (1976). It was thought originally that P-gp was mainly expressed in human cancer
cells causing multidrug resistance (for a review, see e.g. Bosch and Croop, 1996). Later, P-
gp was detected also in many normal human tissues such as placenta, liver, small and large
intestinal epithelium, testes, and endothelial capillaries of brain (Cordon-Cardo et al., 1990).
It has been postulated that the ABCB1/P-gp efflux-transporter plays a critical role in cell
protection because of its ability to pump out not only drugs and other xenotoxins but also
endogenous harmful products of oxidative stress (Huls et al., 2009). There are many P-gp
substrates  including  a  wide  variety  of  compounds  e.g.  many  drugs  such  as  anticancer
drugs, antibiotics, immunosuppressive drugs, and HIV protease inhibitors (Petrovic et al.,
2007; Vähäkangas et al., 2011). There is some evidence that especially those compounds that
are uncharged or weakly alkaline are transported, but also some acidic compounds are
transported by the ABCB1/P-gp transporter (Ceckova-Novotna et al., 2006).  The function of
P-gp  can  be  inhibited  by  many  of  its  substrates  but  there  are  also  inhibitors  such  as
verapamil that have low affinity for P-gp (Huls and Russel, 2009).
In human placenta, P-gp is localized in the maternal-facing apical side of
syncytiotrophoblast where it is highly expressed (Cordon-Cardo et al., 1989; Nakamura et
al., 1997). However, its amount has been shown to decrease with increasing gestational age
(Gil et al., 2005; Sun et al., 2006). There is substantial inter-individual variation in the
expression of placental P-gp, most likely because of genetic polymorphisms (Hemauer et
al., 2010). The regulation of P-gp expression in human placenta is not completely
understood  but  it  is  known  that  it  can  be  modified  by  many  factors  such  as  diseases,
therapeutic drugs, oxidative stress, and the changes in energy metabolism (e.g. for reviews
see Petrovic et al., 2007; Callaghan et al., 2008; Iqbal et al., 2012). For instance, it was
recently  shown  that  hypoxic  conditions  may  increase  ABCB1/P-gp  mRNA  and  protein
expression in term placental explants (Javam et al., 2014).
P-gp  is  able  to  protect  the  fetus  by  restricting  the  transfer  of  compounds  across  the
placenta. In CF-1 mice, which have a spontaneous mutation in the gene mdr1a encoding P-
gp, the teratogenic isomer of avermectin induced more teratogenicity (cleft palate) than in
the control group (Lankas et al., 1998). Lankas and coworkers observed a negative
correlation between the degree of chemical exposure and the expression of P-gp. In the
study of Smit et al. (1999), inhibition of placental P-gp in mice led to increased
concentrations of several therapeutic drugs i.e. saquinavir, digoxin, and paclitaxel in the
fetus. Furthermore, they also found that fetuses with missing mdr1a and mdr1b genes had
been  exposed  to  many  times  higher  concentrations  of  the  drugs  than  fetuses  of  the  same
dam with the normal genotype.
The  effect  of  P-gp  on  the  transfer  of  its  substrates  has  also  been  studied  in  human
placental perfusion. Mölsä and coworkers (2005) studied the transfer of the protease
inhibitor, saquinavir, in both the feto-maternal and in maternofetal directions. They found
that the transfer of saquinavir was 108 fold higher in the feto-maternal direction. They
revealed the impact of P-gp by using P-gp inhibitors PSC833 (valspodar) or GG918, these
drugs increased the maternofetal transfer of saquinavir significantly but did not affect the
feto-maternal transfer. The same effect was noted in the case of the antiviral protease
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inhibitor, indinavir, where P-gp inhibitors increased the maternofetal transfer of the
compound (Sudhakaran et al., 2008). Thus, it seems obvious that P-gp restricts the fetal
exposure of many compounds.
ABCB5/MDR
ABCB5 was cloned in 2003 from normal melanocytes carrying the stem cell marker CD133
(Frank et al., 2003). Thus, this transporter protein was discovered significantly later than P-
gp. The function of ABCB5 is related to stem cell function, cell fusion, and vasculogenic
plasticity (Frank et al., 2011). However, it is also linked to drug efflux because it has been
demostrated to be involved in chemoresistance in human melanoma cells (Frank et al.,
2003; 2005). Recently, ABCB5 was found from the cytotrophoblasts of first trimester
placentas, and trophoblast-derived neoplasms (Volpicelli et al., 2014). In the same study,
the expression of ABCB5 was proposed to decrease with gestational age together with the
disappearance of the cytotrophoblasts. So far, nothing has been published to clarify the
significance and the function of ABCB5 in human placenta.
ABCG2/BCRP
The human breast cancer resistance protein (BCRP) is encoded by the ABCG2 gene. It was
originally cloned from MCF-7/AdrVp, multidrug-resistant human breast cancer cell line
where it conferred resistance against chemotherapeutic agents (Allikmets et al., 1998; Doyle
et al., 1998). BCRP is most highly expressed in placenta, more so than in any other human
tissue (Doyle et al., 1998). In these tissues, it seems to be an important contributer to many
physiological barriers including testis, small and large intestine, and brain (Maliepaard et
al., 2001). Because of the localization of BCRP, it has been claimed that its most probable
physiological  functions  are  to  protect  sensitive  tissues  and  during  pregnancy  one  can
include the fetus in the list.  BCRP has many types of substrates originating from different
groups such as therapeutic and illegal drugs, xenotoxins, vitamins and endogenous
molecules (for recent reviews see e.g. Hahnova-Cygalova et al., 2011; Mao and Unadkat,
2015). The widely studied clinical example of the function of BCRP is the link between high
BCRP expression in acute myeloid leukemia patients and poor clinical outcome of the
disease and resistance to treatments (reviewed in Natarajan et al., 2012).
In the human placenta, the BCRP protein expression is localized on the apical membrane
of syncytiotrophoblast, which would be supported for the protective role for this efflux-
transporter (Maliepaard et al., 2001). The data about the expression during different stages
of gestation is controversial (Meyer zu Schwabedissen et al., 2006; Yeboah et al., 2006).
BCRP  is  also  believed  to  mediate  many  physiological  functions  in  the  placenta  including
placental estrogen synthesis (Grube et al., 2007), differentiation of cytotrophoblasts (Takabe
et al., 2010), and protecting cells from apoptosis (Evseenko et al., 2006). The BCRP protein
expression cen be affected by many factors e.g. by hormones, other endogenous and
exogenous compounds, and pathological conditions (reviewed in Hahnova-Cygalova et al.,
2011). Evseenko and coworkers (2007) have shown that the BCRP expression is commonly
reduced in cases of idiopathic restriction of fetal growth. Interindividual variations in the
properties  of  BCRP  are  thought  to  be  due  to  gene  polymorphisms  which  then  affect  the
levels of the protein (Kobayashi et al., 2005). Over 80 single nucleotide polymorphisms
(SNPs) have been found in the ABCG2 gene (Tamura et al., 2007). For instance, the C421A
variant in the ABCG2 gene, a common SNP in both Japanese and Caucasian populations,
has been shown to reduce the amount of BCRP protein (Kobayashi et al., 2005).
A few human placental perfusion studies have been carried out to investigate the role of
BCRP in transplacental transfer. Pollex and coworkers (2008) found that the feto-maternal
ratio of the antidiabetic drug, glyburide, increased significantly when perfused together
with  the  specific  BCRP  inhibitor,  nicardipine.  Similarly,  the  transfer  of  the  common
heterocyclic amine, PhIP (2-amino-1-methyl-6-phenyl-imidazo(4,5-b)pyridine), was
restricted by BCRP in a human placental perfusion, and the inhibition of the protein
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increased the fetal exposure of PhIP (Myllynen et al., 2008). In the most recent perfusion
study, it was proposed by Feinshtein et al. (2013), that a major phytocannabinoid found in
cannabis, cannabidiol was able to inhibit the function of placental BCRP. Thus, the use of
cannabis during pregnancy may make the fetus more vulnerable to xenobiotics that are
substrates of BCRP.
ABCCs/MRPs
Multi-drug resistance proteins (MRPs) belong to a subfamily that consists of 13 members,
which are encoded by the ABCC1-13 genes (Reviewed in Ni and Mao, 2011). In comparison
with P-gp and BCRP, much less is known about the role of MRPs. In the ABCC family, also
many different polymorphisms in the protein encoding genes have been found (for a
review, see Choudhuri and Klaassen, 2006). Nevertheless, only a few consequences have
been related to ABCC mutations, such as Dubin-Johnson syndrome (hyperbilirubinemia)
(Paulusma et al., 1997; Wada, 2006) or the decreased expression of MRP2 in preterm
placentas (May et al., 2008). Very little is known about the regulation of MRP expression.
However, it is probable that similar factors as described for the other ABC-transporters,
such as hormones, exogenous and endogenous compounds, and different diseases may
affect the expression of MRPs. Recently Kozlowska-Rup and coworkers (2014) have claimed
that in the placentas from mothers with gestational diabetes mellitus, there may be less
MRP1 present than in healthy controls.
MRP proteins are found both in the apical and basal membranes of syncytiotrophoblast.
MRP1 may be involved in important physiological functions e.g. the transport of
unconjugated bilirubin from fetus (Serrano et al., 2002) and delivery of the essential
nutrient, folate to the fetus (Hooijberg et al., 2003). Different MRPs have many substrates in
common but the affinity to the transporter may vary (for reviews see e.g. Ni and Mao, 2011;
Vähäkangas et al., 2011). In addition to the similarity of substrates as with other ABC-
transporters, it does seem that anionic and conjugated compounds are mainly transported
by MRPs (Leslie et al., 2005).
In the human placenta, MRPs 1-3 and MRP5 have been found (Table 3). MRP2 has been
clearly shown to be expressed in the apical membrane of the syncytiotrophoblast, claimed
to be evidence of a protective role for this protein (Meyer zu Schwabedissen et al., 2005a),
whereas MRP1 and MRP5 have been mainly found from the basolateral membrane of
syncytiotrophoblast and from the endothelium of fetal capillaries (Atkinson et al., 2003;
Nagashige et al., 2003). However, there have been suggestions that MRP1 could be found
also from the apical membrane of the syncytiotrophoblast (St-Pierre et al., 2000, Vaidya et
al., 2009). The expression of MRP2 has been claimed to increase with gestational age, which
may indicate its greater role in fetal protection during the late stages of pregnancy, whereas
the amount of P-gp is highest in early pregnancy (Meyer zu Schwabedissen et al., 2005;
May et al., 2008).
2.2.4 Placental xenobiotic metabolism
There are functional xenobiotic metabolizing enzymes also in the human placenta, although
the role of the placenta in xenobiotic metabolism is minor when it is compared to the main
metabolizing organ, the liver (for reviews see e.g. Hakkola et al., 1998; Myllynen et al., 2007;
Vähäkangas et al., 2014). However, fetal exposure can be affected by placental metabolism.,
Some phase 1 (functionalization reactions) and phase 2 (conjugations) metabolic enzymes
have been detected in the human placenta. The expression profile of mRNA and functional
enzymes changes during pregnancy (Pasanen, 1999; Myllynen et al., 2007).  As in other
tissues,  there  is  also  individual  variation  in  the  placenta  in  terms  of  the  expression  of
different enzymes. Furthermore, the gestational age and maternal health both influence the
enzyme expression and functionality (Hakkola et al., 1996a; 1996b).
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The majority of placental CYP enzymes seem to be mainly involved in physiological
steroid metabolism, not in xenobiotic metabolism (Storvik et al., 2014). Functionally,
CYP1A1 is the most significant of the placental xenobiotic enzymes. The basic level of
placental CYP1A1 is very low but it is highly inducible e.g. by cigarette smoking (Pelkonen
et al., 1984; Vähäkangas et al., 1989). From the toxicological point of view, CYP1A1 is an
interesting enzyme because it participates in the metabolism of many toxic substances and
activates several procarcinogens such as benzo(a)pyrene and proteratogens including
isotretinoin and tretinoin (Namkung and Juchau, 1980; Miller et al., 1993). CYP1A1
catalyzes the activity of aryl hydrocarbon hydroxylase (AHH), which has been shown to
correlate positively with DNA binding of the well-known carcinogenic metabolite of
benzo(a)pyrene, benzo(a)pyrene-7,8-diol-9,10-epoxide (Namkung and Juchau, 1980;
Vähäkangas et al., 1989).
The functional CYP enzyme in human placenta with the highest expression throughout
pregnancy is CYP19A1 (aromatase). Its main function is to convert androgens into
estrogens, to assist in the maintenance of pregnancy, and it is involved in fetal sexual
differentiation of gonads (recently reviewed in Vähäkangas et al., 2014). Moreover, because
of its wide substrate binding pocket, the enzyme has many potential substrates. For
instance, CYP19A1 has been shown to participate in the placental metabolism of cocaine, 7-
ethoxycoumarin, and buprenorphine (St-Pierre et al., 2002; Deshmukh et al., 2003). Paakki
and coworkers (2000) have reported the suppression in placental aromatase activity
followed after glucocorticoid therapy.
2.3 EXPERIMENTAL METHODS TO STUDY PLACENTA
2.3.1 Existing methods
Fetal exposure cannot be studied by exposing mothers deliberately to different compounds
during pregnancy. Thus, it is practically impossible to gather systematic in vivo data about
fetal exposure e.g. to new medical drugs. The fetus is exposed when the mother is treated
with medications as well as when the mother is exposed to environmental compounds
unintentionally. Fetal exposure to a large variety of environmental compounds, and drugs
has been shown in vivo by  analyzing  compounds  from  amniotic  fluid,  meconium,  cord
blood, and fetal hair (for reviews see e.g. Barr et al., 2007; Etwel et al., 2014). However, the
time frame of the exposure during pregnancy is difficult to define. From meconium, the
exposure of the two last trimesters can be measured for some compounds such as
organophosphate metabolites, because meconium accumulates in the fetal bowel from 12-
16 gestation weeks onwards (Whyatt and Barr, 2001).
Since there are extensive differences in the structure and function of the placenta
between species (Leiser and Kaufmann, 1994), it is advisable to use models which have a
human origin.  Human placenta, human placenta derived cells, and human placental tissue
pieces hold the potential to replace and reduce the number of animals used for toxicity
testing since they can provide new and relevant information about transplacental transfer
and  related  mechanisms  including  the  function  of  metabolizing  enzymes  and  transporter
proteins (table 4).
2.3.2 Placental explants
Tissue explants
One can collect microscopically identifiable material from human placenta of any
gestational age and from these origins the different types of tissue explants can be derived
(Göhner et al. 2014). The most common tissues are placental villi, blood vessels, different
membranes and decidua (Miller et al. 2005). One major advantage of tissue explants over to
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cell-based experiments is that in tissue, the cell-cell interactions and tissue homeostasis
remain relatively intact. The first studies using human placental explants were conducted
in the 1940s. In these earliest studies, placental endocrine function, oxygen consumption,
metabolism, and transport were studied (reviewed in e.g. Miller et al., 2005; Myllynen and
Vähäkangas, 2013). Later studies have concentrated mostly on cellular processes such as
proliferation, differentiation, syncytial fusion, and apoptosis. For instance, in 1970, it was
found that a low level of oxygen was related to stimulation of cytotrophoblast proliferation
(Fox, 1970). Heikkilä and coworkers (2002) cultured placental tissue explants after the
perfusion experiments and confirmed the integration of their gene construct in placental
cells. Recently, tissue explants have been used in studies of preeclampsia. Orendi et al.
(2011) have summarized two different approaches in the case of preeclampsia: 1) Using
explants from the placentas of uncomplicated pregnancies to identify the different factors
affecting tissue function, adaptation, and survival. 2) Using the explants from placentas
from the problematic pregnancies and comparing them with healthy age-matched controls.
Chorionic villous explant cultures
From the fetal exposure point of view, villous cultures have been exploited in studying the
mechanisms of transplacental transfer such as the regulation, expression and the function
of placental transporters and xenobiotic metabolizing enzymes (Vähäkangas et al., 2011).
Moreover,  villous  cultures  have  been  used  to  study  the  transport  of  small  molecules  and
amino acids (Dancis et al., 1968; Miller and Berndt, 1974). Although the transport of
compounds from the maternal circulation into the syncytiotrophoblast can be studied in
villous cultures, the model is not suitable for the studies of transplacental transfer because
of the lack of continuous membrane (Myllynen and Vähäkangas, 2013). Recently, Lye and
coworkers (2013) utilized placental villous explants to reveal that the supply of oxygen
could alter the protein and mRNA expression of ABCG2 and ABCB1. In first trimester
placentas, mRNA of ABCG2 was induced under hyperoxic (20%) conditions, whereas the
expression of the protein was increased in hypoxic (3%) conditions (Lye et al., 2013). In the
same study, there was no effect on ABCB1 at the mRNA level, but under hypoxic
conditions, the protein expression was increased in the cytotrophoblast/syncytium. In the
term placentas, hypoxic conditions increased the expression of ABCB1 at both the mRNA
and protein  levels,  whereas  the  levels  of  ABCG2 were  not  affected by changes  in  oxygen
tension (Javam et al., 2014). These changes in transporter protein expression may affect fetal
exposure to xenobiotics during pregnancy. Even the acute consumption of ethanol has been
claimed to interfere with placental cell growth and trophoblast migration in the first
trimester villous explants (Lui et al., 2014).
One disadvantage of placental tissue and villous cultures is that they have to be used
freshly  after  delivery  and  thus  it  is  not  possible  to  repeat  the  experiments  with  the  same
placental tissue later (Orendi et al. 2011). Furthermore, the viability of tissue cultures is
limited; their maximum lifetime is only about 11 days even under strictly controlled
circumstances (Di Santo et al., 2003; Miller et al., 2005). The data obtained in some studies
with tissue explants appears to be somewhat unreliable; there are many discrepant results
in the literature originating from different laboratories using different experimental
conditions, and there is also extensive variation in the methods used for evaluation and
preparation of the tissue (reviewed in Miller et al. 2005).
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2.3.3 Cultured cells
Cancer cell lines
There are three main cell lines of human placental origin that are being used in placental
research: BeWo, JEG-3, and JAr cells (e.g. for reviews see Vähäkangas and Myllynen, 2006;
Prouillac and Lecoeur, 2010; Myllynen and Vähäkangas, 2013). Originally BeWo cells were
isolated from the cerebral metastasis of a choriocarcinoma and serially transplanted to the
cheek pouch of the hamster (Hertz, 1959). It was from that culture that Pattillo and Gey
(1968) established the BeWo cell line. Later, the JAr (Pattillo et al. 1971) and JEG-3 cell lines
were isolated (Kohler and Bridson, 1971) from the same original culture. Although
continuous cell lines have a malignant origin, they have been shown to possess many of the
same biochemical and morphological characteristics as trophoblasts in vivo (Orendi  et  al.,
2011). However, there are differences between these cell lines (Table 4). BeWo cells are
undifferentiated cytotrophoblasts with few syncytialized cells while JEG-3 cells have many
similar characteristics as the syncytiotrophoblast. However, JEG-3 cells are able to
proliferate and are mononucleated (Wice et al., 1990; Matsuo and Strauss, 1994), in contrast
to the syncytiotrophoblast which is multinucleated and formed from differentiated
cytotrophoblasts.
Cancer cell lines have been used for many different types of studies on cellular function,
metabolism, and toxicity. For example, cell differentiation, endocrinology, invasion,
immunology, transplacental transfer and related mechanisms e.g. expression and
localization of transporters, cellular uptake, and gene expression have been examined in
these cell lines (Sullivan, 2004; Prouillac and Lecoeur, 2010). If one wishes to examine trans-
trophoblast transfer, then only the cells that form confluent and polarized monolayers can
be used (Bode et al., 2006). Bode and coworkers have devised two models using Transwell®
inserts and Side-bi-Side™ diffusion chambers where the b30 BeWo clone have been shown
to form confluent monolayers; these appear to be the only appropriate human
choriocarcinoma cell line for transfer studies. Poulsen et al. (2009) compared the transfer
rate of four different compounds (caffeine, antipyrine, benzoic acid, and glyphosphate) in
BeWo cells and in human placental perfusion. Interestingly, they found that the overall
ranking of the compounds by their transfer percentage was exactly the same in both
models, although the transfer rate of the compounds was about ten times higher in
placental perfusions.
There are some disadvantages associated with the cancer cell lines. One problem is that
cancer cells have been malignantly transformed and thus are different from primary cells.
There are other examples of differences e.g. the highly different microRNA expression
profile between primary first trimester and term trophoblastic cells, and trophoblastic cell
lines such as JEG-3 (Morales-Prieto et al., 2012). In addition, the mRNA expression profile
has been shown to be very different in primary extravillous trophoblasts and villous
cytotrophoblasts when compared to BeWo and JEG-3 cells (Bilban et al., 2010).
Furthermore, the cell lines have existed for a long time and different strains have been
described. For instance, in BeWo cells, the fusion rate for syncytialization varies from 10%
(Kudo et al., 2003) to 80% (Das et al., 2004) between cell clones. Thus, because of these many
differences, it has been recommended to repeat and confirm especially the most critical
results with some primary models such as primary cells or primary villous explants (Bilban
et al., 2010).
Isolated human primary placental cells
There are several possible methods available to isolate primary cells from placenta at
different phases of gestation (Kliman et al., 1986; Aboagye-Mathiesen et al., 1996; Petroff et
al., 2006). The most commonly isolated cells are cytotrophoblasts, different subtypes of
immune cells, and endothelial cells from either umbilical cord or fetal vessels (Kammerer et
al., 2004; Male et al., 2012; Sölder et al., 2012). The isolation and culture methods for
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primary cells are very laborious in comparison with immortalized or cancer cell lines
(Myllynen and Vähäkangas, 2013). The isolated cells from one placenta can be frozen and
the experiments with cells from a single placenta can be repeated. The advantage of
primary cells is that they represent more closely the physiological cells than do the
malignantly transformed cancer cell lines (Vähäkangas et al., 2011). However, the laborious
isolation process imposes substantial stress on the cells and may alter their normal
physiology (Göhner et al. 2014).
Isolated primary trophoblasts can be used to study xenobiotic metabolism and different
mechanisms affecting transplacental transfer such as efflux and uptake, but not for actual
transfer studies (Table 4) (Myllynen and Vähäkangas, 2013). These undifferentiated
cytotrophoblasts can syncytialize spontaneously but do not proliferate in culture. Primary
cytotrophoblasts readily form aggregates with large intercellular spaces in semipermeable
membrane and thus it is impossible to study polarized transfer (Yui et al., 1994; Liu et al.,
1997). There is only one study describing a tight layer grown of primary cells. Hemmings
and coworkers (2001) succeeded after three cycles of seeding and differentiation to form
overlapping layers of syncytialized cells that created a functional barrier to low-and high-
molecular-weight molecules. However, the method is so difficult and laborious, and the
primary cells can be so easily contaminated, that transfer studies using primary cells have
not become a routine method.
2.3.4 Tissue fractions
Placental microsomes and cytosolic fraction
Placental  microsomal  fraction  can  be  used  to  study  placental  metabolism  and  enzyme
activities. Microsomes are prepared from endoplasmic reticulum by differential
centrifugation (Ostrea et al., 1989). Some characteristic inter-individual differences in
metabolizing enzymes have been demonstrated in microsomal fractions (Vähäkangas et al.,
1989). In addition, some of the metabolizing enzymes are expressed in the cytosol, and thus
also cytosolic fractions can be used to study metabolism (e.g. Partanen et al., 2010).
Placental microvillous and basal membrane vesicles
Initially the idea of preparing membrane vesicles from the surface of term
syncytiotrophoblast was described by Smith and coworkers (1974). Membrane vesicles are
isolated either from basal or from the brush border surface of the term trophoblasts. The
purity of the isolated membranes is important and can be accomplished by many different
methods (Jimenez et al., 2004). The purification is usually confirmed by using different
markers such as the presence of alkaline phosphatase for apical membrane and two marker
proteins, adenylate cyclase and Ά–adrenergic receptor, for basal membrane (Matsubara et
al., 1987; Illsley et al., 1990).
Membrane vesicles have been used to study mechanisms of placental transfer,
transporter expression, and activity in a particular membrane (Boyd, 1991, Glazier and
Sibley, 2006). For instance, the ABC-efflux transporters have been extensively characterized
in membrane vesicles (Reviewed by Vähäkangas et al., 2011). Vesicles have been also used
to determine amino acid uptake (Ruzyski et al., 1978). Furthermore, the expression and
function of thyroid hormone transporters have been examined by using term placental
microvillous plasma membrane vesicles (Loubiére et al., 2012). There is also the possibility
to modify membrane vesicles to overexpress certain transporters to study their specific role
in transfer kinetics (Vaidya et al., 2009; Hemauer et al., 2010). The disadvantage of the
method is that transporter activities have been measured without regulating factors and
thus the results obtained do not completely reflect the function in vivo (Glazier and Sibley,
2006).
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2.4 HUMAN PLACENTAL PERFUSION
2.4.1 Human placental perfusion method and its variations
Human placental perfusion has been in use already for about half a century. In the first
perfusion experiments, the whole human placenta was perfused (Krantz et al. 1962; Panigel
et al. 1962). In 1967, Panigel et al. perfused a single cotyledon but the maternal circulation
was organized through the spiral arterioles. A couple of years later, Schneider and
coworkers (1970) introduced the currently most widely used method to cannulate maternal
side of the placenta by pushing a blunt maternal cannulae into the intervillous space. In
1972, the dual perfusion method was described, where both maternal and fetal circulation
were cannulated (Schneider et al., 1972). However, the last significant modification was
introduced by Brandes et al. (1983) when they used the recirculating (closed) system where
the perfusion medium was recirculated in both maternal and fetal circulation mimicking in
vivo situation.  With  this  model,  both  transplacental  transfer,  and  distribution  between
maternal circulation, placenta, and fetal circulation can be studied. In the non-recirculating
(open) perfusion, the perfusate is not recirculated and it only goes once through the
placenta. In the open configuration, e.g. drug clearance from either maternal or fetal
circulation, or possible accumulation, can be determined (Schneider et al., 1972).
Human  placental  perfusion  has  been  used  to  study  transplacental  transfer  and  related
transfer mechanisms of different compounds (endogenic and environmental compounds,
as well as drugs), possible placental metabolism, normal placental function, pathological
conditions such as preeclampsia, and the accumulation of compounds in placental tissue
(e.g. for reviews see Omarini et al. 1992; Ala-Kokko et al. 2000; Hutson et al. 2011). More
recently placental perfusion has been also used in the studies of placental biology including
fetoplacental vascular function, bidirectional lipid transport across the placenta, and to
examine the effects on trophoblast cells caused by infectious agents (Abumaree et al., 2014).
Among the existing placental models, ex vivo perfusion is closest to the in vivo situation,
because it retains the whole organized tissue structure with its different cell layers (Gohner
et  al.,  2013).  Most  perfusion  experiments  last  2-6  hours,  which  is  enough  for  transfer
studies. The longest-lasting perfusion in the literature continued up to 48 hours, but in
these kinds of extreme cases, the perfusion medium has to be changed every few hours and
glucose has to be added (Polliotti et al., 1996). With some exceptions, the transfer data of
study compounds in human placental perfusion correlates well with the available in vivo
data (Hutson et al., 2011, Vähäkangas et al. 2011). Hutson et al. (2011) have shown that by
taking into account differences in fetal and maternal protein binding and in blood pH, then
the prediction of transplacental transfer of drugs is accurate in comparison to in vivo levels
at steady state. However, in ex vivo perfusion,  it  can  take  up  to  3  hours  before  achieving
steady state with a passively diffusible compound such as antipyrine, with the time
depending on the flow rates of the circulations (Myllynen et al., 2010). In perfusion studies,
pH has usually been set up to 7.4 on both maternal and fetal circulations, whereas normal
physiological values are 7.35 on fetal and 7.4 on maternal side (Reynolds and Knott, 1989;
Hutson et al., 2011).
Applicability of human placenta for perfusions
It  is  highly  relevant  to  use  human placentas  in  perfusion studies,  because  there  are  more
between  species  differences  not  only  in  the  anatomical  structure  and  function  but  also  in
the metabolic capacity of placenta than in any other organ (Leiser and Kaufmann, 1994).
Placentas are available after birth and otherwise discarded. However, in order to ensure the
availability of placentas, it is required that studies have been done in collaboration with a
major hospital capable of providing a sufficient number of births and that the distance
between the perfusion laboratory and the hospital is not too long.
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In most perfusion studies, only term placentas have been used because they are the
easiest target. However, term placentas represent only the situation at the end of
pregnancy. There are a few perfusion studies in the literature where preterm placentas have
been used. Fokina et al. (2011) have published a perfusion study with buprenorphine where
they have used placentas obtained after 30 to 34 weeks of pregnancy, and Holcberg et al.
(2007) perfused placentas from pregnancy weeks 32-36. Nanovskaya et al. (2008) used even
earlier placentas (27-34 weeks) when studying the transplacental transfer of methadone. In
the case of methadone, the maternofetal transfer was 30% lower in preterm placentas than
in term placentas (Nanovskaya et al., 2008), whereas buprenorphine transfer did not change
with the progress of pregnancy (Fokina et al., 2011).
During pregnancy, the placenta consumes as much oxygen as vital organs such as brain,
kidney, and liver (reviewed by Carter, 2000). However, it resists hypoxia and ischemia
better than the other highly oxygenated organs by remaining in a low energy state (Serkova
et al., 2003; Schneider, 2009). The increased oxidative stress in placental tissue is noted
when reperfusion is established ex vivo (Di Santo et al., 2007; Guller et al., 2007). Although
the term placenta is at the end of its lifespan, it retains its functionality for perfusion:
facilitated D-glucose transport remains still three times faster than passive diffusion, amino
acids are transferred via the specific transport system, and placental peptides such as
human placental lactogen and human chorionic gonadotropin are produced (Dancis, 1985).
Placentas have been collected from both cesarean sections and normal deliveries. Cindrova-
Davies et al. (2007) have shown that normal delivery produces more oxidative stress in the
placenta than cesarean section, and these workers claimed that placentas from normal
deliveries do not reflect term placentas at the molecular level. Thus, it could be possible that
placentas from cesarean sections are closer to the in vivo situation.
Perfusion medium
One of the critical issues in perfusion studies is the proteins used and their concentration in
the perfusion medium. Generally only drugs in the free, non-protein bound are more likely
to be active (Kwong, 1985; Svensson et al., 1986).  About 1000 proteins or peptides can be
easily separated from human serum. The most abundant proteins that bind different
compounds  such  as  drugs  are:  albumin,  ΅1-acid  glycoprotein,  lipoproteins,  and
immunoglobulins (reviewed in Kratz and Elsadek, 2012). However, albumin is the most
common because of its high concentration in serum and its small size. The physiologic
concentration of albumin during pregnancy varies between 24-43 g/l in the plasma of the
mother  and  is  the  lowest  towards  the  end  of  pregnancy  with  a  FM-ratio  of  about  1.16  at
term (Larsson et al., 2008). Another important protein that binds xenobiotics is the ΅1-acid
glycoprotein.  Its FM-ratio changes from 0.09 during the first trimester to 0.37 at term
(Krauer et al., 1984).
Traditionally in perfusion studies the same concentration of albumin (2 g/l) has been
used in both circulations (reviewed by Mathiesen et al., 2010). In some perfusion
laboratories, the effect of protein content on the transfer of compounds has been tested. In
the studies conducted by Knudsen´s group, more benzo(a)pyrene (BP) was transferred
when there was a higher albumin concentration in perfusates (30 g/l) (Mathiesen et al.,
2009; Mathiesen et al., 2010; Morck et al., 2010). However, they discussed the possibility of
the  lipid  in  the  albumin  preparation  playing  a  more  important  role.  Nanovskaya  and
coworkers (2008) studied the effect of albumin on placental transfer of rosiglitazone and
glyburide in human placental perfusion.  The FM-ratio of rosiglitazone increased from 0.17
when there was no albumin up to 0.33 with 30 g/l of albumin and the amount retained by
the placental tissue was significantly decreased. The effect of albumin on the FM-ratio of
glyburide was opposite to that found with rosiglitazone. The FM-ratio of glyburide was
decreased from 0.09 with no albumin to 0.03 with 30 g/l of albumin, although the amount
retained by the tissue decreased also in this case. In the study of Gavard et al. (2006),
transplacental transfer of lopinavir combined with ritonavir was investigated with three
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different albumin concentrations (2, 10, and 40 g/l) in the perfusion medium. The transfer
rate decreased from 23.6% to 3.3% when the albumin concentration was increased.
Considering the significance of the protein binding, Hutson et al. (2011) have suggested
that with the current practice of utilizing non-physiological concentrations, human
placental perfusion studies usually overestimate transplacental transfer when the
compound binds in vivo to ΅1-acid glycoprotein, and underestimate the transfer when the
compound binds to albumin in vivo. In fact, they have shown in the cases of bupivacaine,
ropivacaine, and lidocaine that adjusted results from perfusion are more close to in vivo
values than the values achieved by adding human plasma to maternal circulation.
Criteria for successful perfusion and markers for tissue viability
Because of the complexity of the placental perfusion method, many different markers are
needed  to  ensure  the  technical  success  of  perfusion  and  the  viability  and  functionality  of
placenta in ex vivo perfusion studies. If one is interested in evaluating transplacental
transfer, three main criteria should be fulfilled; the integrity of the maternofetal barrier,
overlap of the cannulated maternal and fetal parts of the cotyledon, and the biochemical
functionality of placental tissue. For each criterion, there are different markers that have
been used over the years of perfusion experiments (Table 5).
With respect to the integrity, the most common marker is volume loss (leak) from fetal to
maternal side (Cannell et al., 1988; Pienimäki et al., 1995; Ala-Kokko et al., 2000). The leak is
usually followed throughout the perfusion experiment, and the amount reveals whether or
not the structure of fetal villous trees is intact and the fetal and maternal perfusates are not
in direct contact with each other. However, there is normally a small detectable leak, and
acceptable limit value between different perfusion laboratories has recently varied between
2-4 ml/h e.g. depending on the toxicity of the study compound (Miller et al., 1985; Annola et
al., 2008; Mathiesen et al., 2010; Partanen et al., 2010; Zarek et al., 2013). Mathiesen and
coworkers (2010) have shown that a negative control substance, FITC marked dextran
added into fetal reservoir, could be detected from maternal circulation when leak during
perfusion experiment was > 3 ml/h, and it was not detectable in perfusions with the leak < 3
ml/h. In the same study they also proved that the leak always occurs from the fetal to the
maternal side since when they added FITC marked dextran to maternal reservoir, it never
ended up on fetal side irrespective of the amount of leak. These findings confirm that the
leak is an appropriate marker for assessing the integrity of fetal villous structure in the
perfused cotyledon.
The arterial pressure (ǂ 40 mmHg) on fetal side has also been used as a marker for
physical integrity (Cannell et al., 1988). Unfortunately, also with this value there has been
no consensus reached between perfusion laboratories. Some laboratories have not analyzed
the pressure regularly and in others, the proposed limit values have varied between ǂ 20-30
mmHg and ǂ 60 mmHg (Schenker et al., 1987; Schneider et al., 2003). It has also been
postulated that a leak of 2-3 ml/h reflects tissue integrity accurately, and the additional
value of pressure measurements is questionable (Pienimäki, 1996). Furthermore, the
morphology of placental tissue can be checked later for edema and possible ruptures in the
structure of villous trees or syncytiotrophoblast (Kaufmann, 1985).
Antipyrine has long been the most commonly reference compound with which to
confirm the overlap of perfused maternal and fetal sides of placental cotyledon (Schneider
et al., 1972; Schneider et al., 1979; Brandes et al., 1983; Pienimaki et al., 1995). The
mechanism for antipyrine transfer in human placenta is the flow-dependent passive
diffusion (Challier et al., 1983). Antipyrine has also been widely used to normalize
interindividual differences between placentas. However, if one wishes to assess antipyrine
transfer, then the level of antipyrine in the perfusion medium has to be analyzed after
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Table 5. The criteria and markers used to determine the success of a perfusion
Studied target Marker Interpretation of the result
and limit values
References
Tissue integrity volume loss from fetal
to maternal circulation
2-4 ml/h Miller et al., 1985,
Pienimäki et al., 1995,
Partanen et al., 2010
FITC marked dextrana should not be found from
maternal side
Mathiesen et al., 2010
pressure in the fetal
circulation
20-60 mmHg Schenker et al., 1987,
Schneider et al., 2003
tissue morphology
after perfusion
visually confirmed integrity Kaufmann, 1985
Overlap of the
perfused areas
antipyrineb reference compound,
concentrations between
maternal and fetal side should
equilibrate
Schneider et al.,
1972, Brandes et al.,
1983, Challier et al.,
1983
inulinb as with antipyrine Brandes et al., 1983
tritiated waterb as with antipyrine Schneider et al., 1985
l-glucoseb as with antipyrine Yudilevich et al., 1979
creatinineb as with antipyrine Eaton et al., 1985
oxygen transfer of oxygen from
maternal to fetal side at the
beginning of the perfusion
Wier and Miller, 1985
Viability and
metabolic activity
of placental tissue
glucose glucose consumption is
demonstrated
Illsley et al., 1984
oxygen oxygen consumption and
transfer is demonstrated
Wier and Miller, 1985
hormone production
including e.g. hCGc,
HCS/hPLd, PAPP-Ae,
and leptin
the detection of hormones
from circulations
Wier and Miller, 1985,
Bersinger et al., 1986
lactate increased lactate production
correlates with anaerobic
glucose consumption
Hauguel et al., 1983,
Illsley et al., 1984
ammonia detection of ammonia Hauguel et al., 1983
placental alkaline
phosphatase (PLAP)
indicates microparticles
shredded from the
microvillous membrane
(tissue damage)
Partanen et al., 2012
a=added into fetal circulation; b=added into maternal circulation; c=Human chorionic gonadotropin;
d= Human chorionic somatomammotropin/Human placental lactogen; e=Pregnancy-associated plasma
protein A
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perfusion. The oxygen transfer from maternal to fetal circulation has been used to ensure
the overlap of cannulated parts of the placenta at the beginning of the perfusion experiment
(Wier and Miller, 1985; Mathiesen et al., 2010). In addition to antipyrine, previously also
tritiated water (Schneider et al., 1985), creatinine (Eaton et al., 1985), and L-glucose
(Yudilevich et al., 1979) have been used to show overlap in perfusion studies.
Many markers have been used to confirm the biochemical functionality and viability of
placental tissue in perfusion experiments. The consumption of oxygen and glucose by the
tissue, net oxygen transfer, and lactate production, have been the most typical
measurements (Illsley et al., 1984; Miller et al., 1985; Wier and Miller, 1985). However, also
placental  production  of  specific  hormones  such  as  human  chorionic  gonadotropin  (hCG),
human placental lactogen (hPL), beta 1-glycoprotein, and  pregnancy-associated plasma
protein PAPP-A have been utilized even decades ago (Bersinger et al., 1986). These same
markers  are  still  used  to  confirm  placental  biochemical  activity  and  viability  in  many
perfusion laboratories (for reviews see Mathiesen et al. 2010; Hutson et al. 2011; Myllynen
and Vähäkangas 2013).
2.4.2 Ethical aspects
Research ethics is a wide topic, which should be taken into account in everyday research
(Vähäkangas, 2013). A few studies exist on ethical aspects of human placental perfusions
(Lind et al., 2007; Halkoaho et al., 2010; 2011; 2012). For ethical reasons, the kinetics of
known or potentially harmful compounds cannot be studied in vivo by exposing pregnant
mothers to these compounds. The only acceptable way to study fetal exposure in vivo is to
measure blood concentrations at birth in the maternal and fetal circulation after intentional
exposure (necessary clinical drugs, ethanol, cigarette smoke) or unintentional accidents.
Human placental perfusion offers an ethically acceptable experimental method, which
maintains the structure of organized placental tissue. In the normal situation in Finland, the
placenta is simply discarded. Thus, theoretically human placenta is available for scientific
investigations after birth with maternal consent, if there are no medical reasons to send the
placenta for pathological examination.
The way that the donors feel about donation varies from mother to mother. In the study
of Halkoaho and coworkers (2010), most of the mothers who were given information about
placental perfusion studies, were very interested to participate and agreed with the
scientific use of placentas after birth. Furthermore, the recruiting midwives appreciate the
research use of placentas after birth, and feel that their role is not as laborious as in some
other medical research projects (Halkoaho et al., 2012). However, in the study of Halkoaho
and coworkers (2012), the interviewed midwives felt that discussing about the study with
mothers should happen in a calm place, and stated that recruitment during ongoing labor
was very difficult. From the researcher´s point of view, the importance of voluntariness of
mothers and the seamless collaboration with midwives in the hospital has been regarded as
extremely important (Halkoaho et al., 2011).
All the people working in the hospital including all researchers are expected to adhere to
professional secrecy. Since people handling placentas are exposed to human blood, all
scientists and students working with placenta are vaccinated against hepatitis A and B, and
tetanus, at least in Denmark and in Finland (Mathiesen et al., 2010). In addition, placentas
from mothers with any known chronic infectious diseases are generally not used.
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3 Aims of the Study
Human placental perfusion is a widely used method to study transplacental transfer of
xenobiotics. The perfusion of human placental cotyledon has been in use for some decades
but there are differences between research models and the method has not been validated
as a toxicity test. The general aim of this study was to provide additional information about
the  role  of  human placenta  in  fetal  exposure  by human placental  perfusion.  Furthermore,
this study aimed to increase knowledge of the significance of placental characteristics in
human placental perfusion studies to promote further development of the method.
Accordingly, the specific objectives of this study were:
1. To characterize the toxicokinetic properties of BP in human placenta.
2. To determine the effect of ethanol on transplacental transfer of NDMA, PhIP and
nicotine.
3. To find out the role of ABCG2 in the transplacental transfer of PhIP by using the ABCG2
inhibitors buprenorphine and THC.
4. To determine the significance of placenta and birth related factors on the success of
placental perfusion.
5. To evaluate the validation status of human placental perfusion as a toxicity test
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4 Materials and Methods
4.1 REAGENTS AND STUDY COMPOUNDS
All  the  used  reagents  and  their  origin  are  listed  in  the  original  papers  I-IV.  The  physico-
chemical properties of the studied compounds are summarized in Table 6.
Table 6. The chemical properties of studied compounds.
Compound Chemical structure Molecular
weight
(g/mol)
Solubility in
water
(mg/l)
IARC
classification for
human
carcinogenicity
Benzo(a)pyrene 252.31 0.00162 1
(IARC, 2010)
NDMA 74.08 1x106 2A
(IARC, 1978)
PhIP 224.26 407.1 2B
(IARC, 1993)
Buprenorphine 467.65 0.636 NE
THC 314.47 2800 NE
Ethanol 46.07 1x106 1
(IARC, 1988)
Nicotine 162.23 1x106 NE
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International Agency for Research on Cancer (IARC) classifications:
Group 1: Carcinogenic to humans
Group 2A: Probably carcinogenic to humans
Group 2B: Possibly carcinogenic to humans
Group 3: Not classifiable as to its carcinogenicity to humans
Group 4: Probably not carcinogenic to humans
PhIP=2-amino-1-methyl-6-phenyl-imidazo(4,5-b)pyridine; NDMA=N-nitrosodimethylamine; THC=Ʃ9-
tetrahydrocannabinol; NE=not evaluated by IARC
4.2 OVERVIEW OF MODELS AND METHODS
Table 7. Overview of models and methods used in the studies.
Model Studied
compound
Type of study Analytical method Publications
Human placental
perfusion
Antipyrine transplacental transfer HPLC, LC-MS I,II,III,IV
Benzo(a)pyrene
(BP)
transplacental transfer
and tissue accumulation
BPDE-DNA adducts
Liquid scintillation
counting
SFS, 32P-postlabelling
I
NDMA transplacental transfer Liquid scintillation
counting
II
PhIP transplacental transfer Liquid scintillation
counting
II,III
Ethanol transplacental transfer COBAS®, clinical
chemistry analyzer
II
Nicotine transplacental transfer LC-MS II
BeWo cells
(human
trophoblastic
cancer cells)
PhIP cellular uptake Liquid scintillation
counting
III
MCF7 cells
(human breast
adenocarcinoma
cells)
Ethanol ABCG2 inhibition Flow cytometry II
BPDE= benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide; PhIP=2-amino-1-methyl-6-phenyl-imidazo(4,5-
b)pyridine; NDMA=N-nitrosodimethylamine
4.3 HUMAN PLACENTAL PERFUSION
4.3.1 Recruiting of mothers and other ethical aspects
Mothers to the studies were recruited by midwives in the maternity wards of the Oulu
University Hospital (I) or the Kuopio University Hospital (II-IV). Mothers were given both
oral and written information about the study, and they had an opportunity to ask about the
study from the midwife. Mothers were also told that their participation was voluntary. By
signing the informed consent, they agreed to the donation of the placenta to be used in the
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perfusion studies. All placentas were anonymized and mothers cannot be traced
subsequently. Placentas were received from both normal deliveries and cesarean sections.
In the case of cesarean section, mothers were recruited when they arrived in the hospital,
either the day before the cesarean section or on the same morning at a couple of hours
before the operation. In the case of normal deliveries, the recruiting occurred also in
hospital. Because mothers enter hospital usually after they already are in labour, most of
the mothers were recruited while in labour. Only healthy mothers with normal pregnancy
were asked to participate.
4.3.2 Perfusion procedure
In all publications, the placental perfusion was carried out similarly. A dual recirculating
method was used where both fetal and maternal sides of a single cotyledon were perfused
separately (Figure 2 in paper IV).  The  perfusion  method  was  based  on  the  technique
described by Schneider et al. (1972) and Brandes et al. (1983) and has been published with
minor modifications in the studies by our group (Annola et al., 2008; Partanen et al., 2010).
The perfusion form (see supplementary material) from every perfusion was filled out in all
studies, in addition to the detailed notes in personal laboratory notebooks.
Before  the  actual  perfusion  experiment,  the  perfusion  of  fetal  side  was  started  with
heparinized Krebs-Ringer phosphate buffer (KRB). The content of perfusion medium was
kept constant in all perfusions and in both the circulations (Table 8). Studied compounds
were always added into maternal circulation and thus only transfer from the maternal to
the fetal side was studied. The same flow rates of artificial circulations were maintained
throughout the studies: on the maternal side 9 ml/min and on the fetal side 3 ml/min. The
perfusion procedure used in these studies is described in detail in the publication number
IV.
Table 8. The ingredients and their role in perfusion medium
Ingredient Final concentration Role Company
RPMI 1640, cell
culture medium
base of the perfusion medium Gibco or Sigma
L-glutamine 0.29 mg/ml essential amino acid that
cannot be produced by human
cells
Gibco, Paisley,
Scotland
Penicillin-
streptomycin
100 IU/ml prevents microbial growth Gibco, Paisley,
Scotland
Sodium pyruvate 1 mmol/l source of energy Lonza, Vervier,
Belgium
Non-essential
aminoacids
0.01 ml/l used for protein production
amino acids, which are usually
produced by the cells from
other amino acids
Cambrex Bio
Science, Vervier,
Belgium
Dextran 2 mg/ml plasma expander to increase
osmotic pressure
Sigma-Aldrich,
Stenheim, Germany
Heparin 25 IU/ml prevents coagulation of residual
blood
Leo Pharma, Malmö,
Sweden
Albumin 2 mg/ml plasma protein, increases
osmotic pressure
SPR, Finland and
Sanquin,
Amsterdam,
Netherlands
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4.3.3 Criteria of successful perfusions
There  were  two main criteria  throughout  the  studies  (publications  I-IV)  for  an acceptable
placental perfusion experiment. In the assessment of the integrity of fetal circulation, the
volume loss (leak) from fetal to maternal circulation was followed throughout the perfusion
experiments. Based on the literature (Miller et al., 1985; Mathiesen et al., 2010) and our own
former experience, ǂ3 ml/h was selected as the acceptable leak from the fetal side. To
confirm the overlap between perfused maternal and fetal sides of the placenta, a widely
used reference compound antipyrine was used in all perfusions. The kinetics of the
passively diffusible antipyrine in human placenta is well known (Schneider et al., 1972;
Challier et al., 1983). During the studies, two different concentrations of antipyrine were
used (25 µg/ml or 100 µg/ml). The third marker followed was the glucose consumption of
the perfused tissue, which reflects the viability and metabolic activity of the tissue. In all
perfusions, glucose was consumed. According to these criteria, the success rate from
available data was 43% (38/88). For the calculation of the success rate only the placentas
that were successfully cannulated and attached to the perfusion apparatus were taken into
account. Unfortunately, complete data for this calculation was not available from all
perfusion projects.
Table 9. Placental perfusions carried out in this study
Compounds and concentrations Number of successful
perfusions
Perfusion time (h) Publication
BP (0.1 µM) 4 6 I
BP (1 µM) 2 6 I
BP (10µM) 4 2 IV
BP + Verapamil (0.1 µM + 1 µM) 4 6 I
Ethanol (2 ‰) 4 2 II
Ethanol + PhIP (2 ‰ + 2 µM) 4 4 II
Ethanol + NDMA (0.5 ‰ + 1 µM) 2 4 II
Ethanol + NDMA (2 ‰ + 1 µM) 5 4 II
Ethanol + Nicotine (2 ‰ + 15 µM) 5 4 II
Nicotine (15 µM) 5 4 II
PhIP (0.2 µM) 1 4 III
PhIP + BUP (0.2 µM+ 0.02 µM) 1 4 III
PhIP + BUP (0.2 µM + 0.2 µM) 3 4 III
Antipyrine (25 µg/ml) 3 4 IV
Antipyrine (100 µg/ml) 3 4 IV
Antipyrine (500µg/ml) 3 4 IV
BP=Benzo(a)pyrene; BUP=buprenorphine; NDMA=N-nitrosodimethylamine; PhIP=2-amino-1-methyl-6-
phenyl-imidazo(4,5-b)pyridine
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4.4 CELL CULTURES AND RELATED METHODS
4.4.1 BeWo cells, BP exposure, and uptake assay (I, III)
The BeWo (human choriocarcinoma) cell line was originally purchased from American
Type Culture Collection (ATCC. Manassas, VA, USA). Cells were grown and treated as
described in publication I. The cells were tested to be free from mycoplasma by using
separate mycoplasma detection kit (MycoAlert®, Cambrex), which is able to detect possible
mycoplasma enzymes. BeWo cells were treated with benzo(a)pyrene (BP) and analyzed for
BPDE-DNA-adducts as a sign of BP metabolism (I).
The  possible  effects  of  ABCG2  inhibitors,  buprenorphine  (BUP)  and  ̇9-
tetrahydrocannabinol (THC) on cellular uptake of the known ABCG2 substrate, PhIP, were
studied  (III). Cells (1x105 per well in 12-well plate) were incubated with five different
concentrations of BUP or THC and the specific ABCG2 inhibitor KO143 at 37 °C for 30
minutes (Ceckova et al., 2006). Pre-incubation medium was removed by suction and then
incubated again with the same compounds as earlier with simultaneously added 2 µM
PhIP in HBSS-glucose. The plates were incubated at 37 °C for 30 minutes. Incubation
medium was collected and cells were washed twice with ice cold HBSS-glucose. Finally the
cells were broken down by lysis buffer (Triton X-100) for 3 hours. The amount of PhIP from
lysates and incubation medium was measured by liquid scintillation counting.
4.4.2 MCF7 cells and ABCG2 inhibition assay (II)
Originally the MCF-7 (human breast cancer adenocarcinoma) cells were received as a gift
from  Professor  Taina  Turpeenniemi-Hujanen  from  the  Department  of  Oncology  and
Radiology, Oulu University Hospital, Finland. Afterwards, the cells were cultured long-
term with 10 nM mitoxantrone to induce ABCG2 overexpressing cells (Kummu et al., 2012).
Cells were grown and exposed as described in the paper II.
The possible effects of ethanol on the function of ABCG2 were tested in the ABCG2
inhibition assay. The well-known ABCG2 inhibitor, fumitremorgin C, was used as a
positive control. The assay is based on the intracellular retention of mitoxantrone in MCF-7
cells. Details of the method are described in the paper II.
4.5 DNA ADDUCT ANALYSIS
4.5.1 Synchronous fluorescence spectrophotometry (I)
BPDE-DNA adducts in placental tissue and cell culture experiments were analyzed using
synchronous fluorescence spectrophotometry (SFS) in Oulu (Vähäkangas et al., 1985). The
method for DNA isolation and the interpretation of the results are described in paper I.
4.5.2 32P-postlabelling (I)
BPDE-DNA adducts in placental tissue samples and cell culture experiments were also
analyzed by the 32P-postlabelling assay in the laboratory of Dan Segerbäck in Karolinska
Institutet, Stockholm, Sweden. The dinucleotide monophosphate version of the method
with minor modifications was used (Randerath et al., 1989; Plna et al., 1999). The separation
of adducts was carried out by thin-layer chromatography (TLC), and the outcome was
visualized and quantified using Phosphoimage analysis (I).
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4.6 ANALYSIS OF SAMPLES
4.6.1 Scintillation counting (I,II,III)
Both 3H- (BP) and 14C- radiolabelled (PhIP, NDMA, BP) compounds were used in placental
perfusion experiments (I-III). 14C-PhIP was used in the uptake assay (III). The radioactivity
of samples was analyzed by scintillation counting using liquid scintillation cocktail (Hi-Safe
3, Perkin Elmer). Details of sample volumes, preparation, and specific activities of the
studied compounds are reported in the original papers.
4.6.2 HPLC (I-IV)
Antipyrine was analyzed from the perfusion samples by high pressure liquid
chromatography (HPLC). Details of sample preparation and the methods used, can be
found in publications I-IV. Two different sets of equipment were used because the analyses
for paper I were done in Oulu and for papers II-IV in Kuopio. The flow rate of the isocratic
run was 1 ml/min. The mobile phase consisted of a mixture of acetonitrile and 20 mM
KH2PO4 buffer solution, but the proportions differed between the methods in Oulu and in
Kuopio as can be seen in the original papers.   A standard calibration curve for antipyrine
was determined for every time of analysis.
4.6.3 LC-MS/MS (II)
The  levels  of  nicotine  and  antipyrine  in  nicotine  perfusions  and  perfused  tissue  samples
were analyzed simultaneously with LC-MS/MS. In this case, antipyrine was analyzed only
by this method because it  could be done together with nicotine analysis.  The method and
the preparation of samples are described in detail in paper II. At the same time, also a
standard calibration curve for both compounds was determined.
4.6.4 RT-qPCR (III)
Real-time reverse transcription polymerase chain reaction (RT-qPCR) was used to analyze
mRNA  levels  of  ABCG2  or  CYP1A1  in  BeWo  cells  to  compare  the  effects  of  different
concentrations of BUP or THC (III). The preparation of samples and other details of the
method have been described by Huuskonen et al. (2013).
4.6.5 Cobas (II)
Ethanol concentrations from perfusion samples were analyzed in the Eastern Finland
Laboratory Centre (ISLAB) by a Roche-Hitachi cobas® 6000 clinical chemistry analyzer
(Hitachi Corporation, Tokyo, Japan) using the Ethanol Gen. 2 enzymatic method of Roche
Diagnostics. The functional principle is introduced in paper II.
4.6.6 Assay for ethoxyresorufin O-deethylase (EROD) activity (I)
EROD activity was determined in placentas perfused with BP. The preparation of
microsomal fractions from the tissue was carried out as described by Myllynen et al., 2008.
The protein content of the fractions was measured using the Bradford method (Kruger et
al., 1994). Details are described in paper I.
4.7 STATISTICAL CALCULATIONS
Statistical calculations were performed using GraphPad Prism 5.0 and SPSS as described in
the original papers (I-IV). The main statistical tests used were: one-way ANOVA followed
by Tukey´s post hoc test, two-way ANOVA followed by Bonferroni post-test, ANOVA with
Huynh-Feldt, and two-tailed Pearson correlation. The results are presented as mean ± SD or
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as the correlation coefficient. A p-value less than 0.05 was regarded as statistically
significant.
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5 Results
5.1 TRANSPLACENTAL TRANSFER (I-IV)
5.1.1 Transplacental transfer of the studied compounds (I-IV)
All the studied xenobiotics crossed human placenta from the maternal to the fetal side in
placental perfusion. However, there were differences in transfer rates between the
compounds as can be seen in table 10.
Table 10. FM-ratios of the studied compounds in the placental perfusion experiments. The table
has been arranged along the transfer rate of the compound in relation to antipyrine.
Compounds and
initial concentrations
n FM-ratio at
120 min
(mean±SD)
FM-ratio at
180 min
(mean±SD)
FM-ratio at
240 min
(mean±SD)
Transfer in relation
to antipyrine
(mean±SD)a
NDMA 1 µM
(+ethanol 2 ‰)
5 0.92±0.14 1.05±0.08 1.12±0.11 108.3±15.1
NDMA 1 µM
(+ethanol  0.5 ‰)
2 0.92 1.04 1.12 108.3±4.4
Ethanol 2 ‰ 4 0.82±0.11 - - 106.9±8.2b
NDMA 1 µMc 5 0.50±0.14 0.83±0.14 0.95±0.10 106.1±10.2
Antipyrine d 9 0.85±0.16 0.93±0.11 0.97±0.09 100
Nicotine 15 µM 5 0.80±0.07 0.89±0.04 0.94±0.07 97.5±9.7
Nicotine 15 µM
(+ethanol 2 ‰)
5 0.77±0.04 0.95±0.07 0.91±0.08 95.8±8.9
PhIP 0.2 µM 1 0.53 0.71 0.72 74.6
PhIP 0.2 µM (+BUP
0.02 µM)
1 0.53 0.63 0.68 65.9
PhIP 2 µM (+ethanol
2 ‰)
4 0.49±0.12 0.60±0.11 0.63±0.13 65.6±15.4
PhIP 2µMe 0.50±0.11 0.59±0.07 0.66±0.07 63.6±8.5
PhIP 0.2 µM (+BUP
0.2 µM)
3 0.52±0.12 0.59±0.15 0.62±0.15 59.7±15.5
BP 0.1 µM 4 0.22±0.16 0.34±0.20 0.48±0.30 37.8±20.7
BP 0.1 µM
(+verapamil 1µM)
4 0.09±0.03 0.20±0.06 0.34±0.19 33.5±11.0
BP 10µM 4 0.03±0.01 - - 3.9±1.4b
BP=benzo(a)pyrene; BUP=buprenorphine; NDMA=N-nitrosodimethylamine; PhIP=2-amino-1-methyl-6-
phenyl-imidazo(4,5-b)pyridine; FM=fetomaternal
a As percentage: FM-ratio of the studied compound/FM-ratio of antipyrine x100, at 180 minutes; b 120
min; c Data published earlier by Annola et al. (2009); d Data combined from perfusions with three different
concentrations; e Data published earlier by Myllynen et al. (2008)
38
Fetal to maternal concentration ratios (FM-ratios) from perfusions were compared with
the FM-ratios of the simultaneously added reference compound antipyrine to reflect the
transfer rate of the compound compared to the passively diffusible antipyrine. The reason
for the choice of FM-ratios at 3 hours is that normally the equilibrium of antipyrine in
maternal and fetal circulations is achieved at that time with the perfusion settings used in
these studies. In table 10, antipyrine data from perfusions with different antipyrine
concentrations is combined, because there were no statistically significant differences in the
FM-ratios of antipyrine when using different antipyrine concentrations (IV).
According to our results, the order of the efficiency by which compounds cross human
placenta in the placental perfusion is as follows: Ethanol>NDMA>antipyrine>
nicotine>PhIP>BP.  Thus,  it  is  possible  to  consider  that  there  are  also  other  transfer
mechanisms involved in  the  transfer  than simply passive  diffusion.  In  the  case  of  PhIP,  it
has been shown previously that the transplacental transfer is restricted by ABCG2
(Myllynen et al., 2008).
In addition, the combinations of different compounds were studied to examine potential
interactions in the transplacental transfer. Ethanol was combined separately with NDMA,
nicotine,  and  PhIP.  However,  there  were  no  statistically  significant  differences  in
transplacental transfer in short-term perfusion studies. Only the transfer of NDMA seemed
to be slightly increased by ethanol but this effect was not statistically significant (Table 10)
(II).
5.1.2 The effect of ABC-transporters on transplacental transfer (I-III)
The effect of the well-known ABCB1/P-glycoprotein inhibitor, verapamil, on the
transplacental transfer of BP was studied in placental perfusion but no major effects were
detected. In fact, against expectations, the transfer of BP from maternal side to fetal side
was somewhat slower with verapamil than without the drug.
The possible inhibitory effect of ethanol on ABCG2 was studied in the ABCG2 inhibitory
assay.  Fumitremorgin  C  which  was  used  as  a  positive  control  clearly  inhibited  the
intracellular retention of mitoxantrone in MCF-7 cells. Ethanol exerted no effect on the
function of ABCG2 at any tested concentration (0.5‰, 2‰, and 2%).
The role of potential ABCG2 inhibitors, THC and BUP, on the uptake of PhIP was
studied in BeWo cells. The uptake of PhIP, which is an ABCG2 substrate, was increased by
BUP more than by THC, and almost as effectively as by the specific ABCG2 inhibitor
KO143, although not statistically significantly. However, in placental perfusion studies, the
transfer of PhIP in the presence of BUP surprisingly tended to be decreased rather than
increased, an opposite effect as expected (Table 10).
5.2 FORMATION OF PLACENTAL BPDE-DNA ADDUCTS (I)
Placental benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) DNA adducts were
analyzed in the tissue samples before and after perfusion of 12 placentas perfused with BP.
Adducts were analyzed by two different methods, 32P-postlabelling assay and synchronous
fluorescence spectrophotometry (SFS). Two placentas were perfused with a relatively high
dose  of  BP  (1  µM).  In  one  of  these  perfused  placentas,  high  levels  of  DNA  adducts  were
found in perfused tissue with both of the methods. The SFS result corresponded
approximately to the adduct level of 1.28 fmol BPDE/µg DNA. BPDE-treated DNA was
used as a positive control in 32P-postlabelling analysis. All other samples contained only
background level of BPDE-DNA: the samples taken from the same placentas before
perfusion, the perfused tissue from the other BP-perfusions, as well as the placentas
without BP exposure (n=2). The mean background level (±SD) of bulky DNA adducts was
1.5±0.7 adducts/108 normal nucleotides or 0.047 fmol adducts/µg DNA.
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5.3 PLACENTAL AND BIRTH RELATED FACTORS AND SUCCESS OF
PERFUSION (IV)
The study of elucidating the effect of birth related factors on the success of perfusions was
made possible by the analysis of the data of all the perfusions carried out in the same
laboratory with the same perfusion method. The data from over 100 perfusions was pooled
and analyzed to examine whether or not there was a potential relationship between the
clinical  data  and  two  major  criteria  of  successful  perfusion.  It  was  intended  to  clarify
whether the volume loss from fetal to maternal side (leak), or transplacental transfer of
antipyrine, was affected by the way of delivery, length of pregnancy, or placental weight. A
negative correlation was found with an increasing age of placenta and antipyrine transfer
in placental perfusion studies (Figure 3). The age of the placenta varied between 35-42
pregnancy weeks. Otherwise, no correlations were detected between the other clinical data
and the perfusion outcome.
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Figure 3. Fetal to maternal concentration ratios of antipyrine. A) at 120 minutes (n=83,
R2=0.066, P<0.05) and B) at 180 minutes (n=77, R2=0.157, P<0.005).
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6 Discussion
6.1 ROLE OF PLACENTA IN FETAL EXPOSURE
6.1.1 Placental toxicokinetics of xenobiotics
In this study, placental transfer from the maternal to the fetal direction of all the examined
compounds, representing known carcinogens and social drugs, was confirmed by
perfusing term human placentas (I-IV). The acquired information is in agreement with
earlier studies demostrating that placenta is a poor barrier against most xenobiotics (for
reviews e.g see Barr et al., 2007; Myöhänen and Vähäkangas, 2011; Etwel et al., 2014).
However,  it  has  to  be  kept  in  mind  that  the  placenta  develops  throughout  pregnancy
whereas  the  method  as  carried  out  in  this  thesis  offers  information  only  about  the  term
placenta. It seems that there are only a couple of placental transfer studies where preterm
placentas have been perfused because such perfusions have appeared to be too difficult for
routine use (Nanovskaya et al., 2008; Fokina et al., 2011). One difficulty is that the
availability of earlier placentas is much more restricted than the availability of term
placentas.
There was variation in the rate of placental transfer between the studied compounds,
although the transfer rate of the reference compound, antipyrine, remained at the same
level throughout the studies (IV). Since the transfer of diffusible compounds is affected by
flow rates (Challier et al., 1983), in all studies the same perfusion conditions were used
including flow rates in both maternal and fetal circuits. The most likely reason for the
variation is the difference in the physico-chemical properties of the compounds (Audus et
al., 1999; Syme et al., 2004). These compound-dependent features include molecular weight,
lipid solubility, and binding to plasma proteins. With respect to the study compounds, the
highly lipid soluble benzo(a)pyrene was the compound which displayed the greatest
differences from the kinetics of antipyrine (BP) (I).
There are two major toxicokinetic mechanisms present in human placenta which can
affect transplacental transfer i.e. transporter proteins and xenobiotic metabolizing enzymes
(Vähäkangas and Myllynen, 2006). Chemicals can also accumulate in placental tissue (Ala-
Kokko et al., 1995). Furthermore, the simultaneous exposure to different compounds can
cause interactions via altered function of transporters or metabolic enzymes (for reviews
see e.g. Liu et al., 2011; König et al., 2013), or via direct cellular effects (Williams and Barry,
2004) and thus affect the transfer of the chemicals through biological membranes.  This is
important because in real life, maternal exposure occurs always to many compounds at the
same time. Human placenta expresses a variety of different transporter systems
(Ganapathy et al., 1999; Prouillac and Lecoeur, 2010). For example, ABC-efflux transporters,
which are mainly expressed in human placenta on the site of maternofetal transfer, play an
important  role  in  the  transplacental  transfer  of  chemical  compounds  (Vähäkangas  and
Myllynen, 2009). The human placental perfusion can be used to study the involvement of
efflux-transporters in placental transfer (Vähäkangas et al., 2011; I; III). One possibility to
study transfer mechanisms is to undertake cellular uptake studies in cell culture (III).
Human placenta expresses a variety of metabolizing enzymes, although the selection is
more restricted and activity levels are very low compared to those in liver (For reviews, see
Pasanen, 1999; Myllynen et al., 2009; Prouillac and Lecoeur, 2010). The possibility of
exploiting short-term placental perfusion studies (4-6 h) to clarify placental metabolism has
been shown earlier for oxcarbazepine (Pienimäki et al., 1997), and aflatoxin (Partanen et al.,
2010). One technique to demonstrate metabolism is to determine metabolites from the
perfusion medium as done by Pienimäki et al. and Partanen et al. (2010). Another way to
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demonstrate metabolism is to analyze macromolecular adducts of reactive metabolites
(Vähäkangas et al., 2014, I).
6.1.2 Placental transfer and metabolism of benzo(a)pyrene
It is clear that the fetus is exposed to benzo(a)pyrene (BP) via maternal exposure. The fetal
exposure to this most abundant PAH-compound in tobacco smoke has been proven by the
findings of BPDE-DNA adducts from cord blood (Mumford et al., 1993; Arnould et al.,
1997; Topinka et al., 2009; for a recent review see Vähäkangas et al., 2014). In the present
study,  the  maternofetal  transfer  of  BP  was  significantly  lower  than  the  transfer  of  the
passively diffused reference compound antipyrine, inidicating that its transfer is restricted
in human placenta.
A year before the publication of paper I, Mathiesen and coworkers (2009) investigated
transplacental transfer of BP; it was significantly lower than in the present study with the
same albumin concentration as used here or with no albumin present at all. However, the
physiological concentration of human serum albumin increased the transfer to the same
level as in paper I. In in vitro incubations with human serum and BP, Aarstad and
coworkers (1987) found that 90-95 % of BP in human serum bound to lipoproteins and the
rest to albumin. Thus, it is possible that increase in the transfer of BP found in the study of
Mathiesen et al. (2009) was related to the lipoprotein present in their albumin preparation,
especially caprylic acid (fatty acid), which may promote BP transfer through the placenta as
also speculated by Mathiesen et al. (2009). In the present transfer studies, only a 1/15th of
the physiological human serum albumin concentration was used.
The recovery of BP varied substantially in the present perfusion experiments.
Radiolabelled 3H-BP was used since radioactivity can be readily determined from the
perfusion medium. However, the possible exchange of tritium with water has to be
considered as one of the reasons for variation in the recovery and the different transfer rates
compared to transfer data provided by Mathiesen et al. (2009). Nonetheless, the relatively
short perfusion time and variations between perfusions do not support this mechanism as
the only reason. Another possible explanation is binding of the compounds to the perfusion
equipment. The Danish group (Mathiesen et al., 2009) reported that 14C-BP did not bind at
all to their tubings, whereas in our recent experiments in perfusion equipment without a
placenta (IV), the recovery of the 14C-BP from the maternal side tubing was only 17-45% in
4 hours. The significance of binding to tubing emphasizes the importance of describing all
of the details including materials in perfusion reports. Thus, the materials used in the
perfusion system may affect the results and this clearly highlights the importance of testing
the recovery before conducting actual experiments with placentas.
Indirect genotoxic carcinogens need metabolic activation before they are converted into
their toxic forms (Pelkonen and Vähäkangas, 1980). BP is a typical indirect carcinogen
which needs to be metabolized to its carcinogenic form, benzo(a)pyrene-7,8-dihydrodiol-
9,10-epoxide (BPDE). It has been shown in placental microsomes in vitro that  BP  may  be
metabolized by human placenta (Vähäkangas et al., 1989; Sanyal et al., 2007). BPDE-DNA
adducts have also been analyzed from placental tissue after birth (Manchester et al., 1988),
although the site of metabolism remains unclear because in vivo there is metabolism also in
mother and fetus (for a review, see Hakkola et al., 1998).
In this study BPDE-DNA adducts were found from one of the two placental cotyledons
perfused with 1 µM concentration of BP, but not from the control tissue samples taken
before  perfusion  or  pefused  tissue  when  lower  concentrations  of  BP  (0.1  µM)  were  used.
This indicates that human placenta maintains its metabolic activity also after birth and the
placenta  is  able  to  metabolize  BP  in  short  term  (6h)  perfusion  studies  (I). However, no
BPDE-DNA adducts were detected after 2 hours of perfusion (unpublished data). Despite
the small number of experiments, the finding was clear. The analytical technique,
synchronous fluorescence spectrophotometry (SFS), is very sensitive (1x107 nucleotides) and
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very specific for BPDE-DNA (Vähäkangas et al., 1985). Nonetheless, further studies will be
needed to confirm the present finding. In additional cell experiments, BPDE-DNA adducts
were  found  in  BeWo  cells  exposed  to  BP,  a  result  which  supports  the ex vivo perfusion
results that placental tissue is truly able to metabolize BP (I).
The placental metabolism of BP has been shown in human placental microsomes, in
which BP is metabolized mainly by CYP1A1 (Vähäkangas et al., 1989; Lagueux et al., 1999;
Stejskalova and Pavek, 2011). We found that the activities of CYP1A1-catalyzed EROD
enzyme, determined from placentas before and after perfusion, varied extensively (I). The
initial EROD activity was clearly higher in the placenta with BPDE-DNA adducts than in
the other placentas, i.e. reflecting interindividual variation. Although it is known that
tobacco smoke and PAHs induce CYP1A1 (Pelkonen et al., 1984; Pasanen et al., 1988;
Vähäkangas et al., 1989), the EROD activity was not increased significantly during the 6
hours of perfusion. CYP1A1 is the most significant of the placental xenobiotics
metabolizing CYP enzymes; it is expressed and functional throughout the pregnancy and it
is subjected to significant interindividual variation (Hakkola et al., 1996). The amount of
placental CYP1A1 can be affected by genetic factors but also by the maternal health status,
as well as by the different toxins that are able to induce CYP1A1 (Stejskalova and Pavek,
2011). It is thus clear that there is interindividual variation in the potential of the placenta to
undertake xenobiotic metabolism and this could probably cause harmful effects on the fetus
and subsequently influence the outcome of pregnancy. In conclusion, cigarettes as a source
of BP and as an inducer of CYP1A1 may represent a true threat to the developing fetus if
the mother smokes during pregnancy.
6.1.3 The role of the ABC-transporters in the transplacental transfer
The  possible  role  of  the  P-glycoprotein  (P-gp)  in  the  transfer  of  BP  was  studied  by
incorporating the well-known P-gp antagonist verapamil (1 µM) (Tsuruo et al., 1981; Kim
2002) simultaneously with BP into maternal circulation during placental perfusion. The
protective role of P-gp in placenta during pregnancy has been well described in mice
(Lankas et al., 1998; Smit et al., 1999). The inhibition of efflux-transporter function in the
brush border membrane leads to an increase in the transfer of P-gp substrates (for a review,
see e.g. Vähäkangas et al., 2011). However, in contrast to expectations, in the presence of the
P-gp inhibitor, verapamil, the transfer of BP was more limited than was the case when the
inhibitor was not present. Because the transfer of antipyrine was also slower, one reason to
account for this result is that verapamil dilated the blood vessels and thus lowered the
perfusion pressure (Benowitz, 1995). It has been shown that blood flow rates in the placenta
significantly affect the transplacental transfer of certain compounds (Faber, 1977; Bassily et
al., 1995). This present result is in line with the study of Schuetz et al. (1998) in which the
transfer of BP through the cell membrane in pig kidney epithelial cells (LLC-PK1) was not
affected by altering P-gp function. On the other hand, Yeh and coworkers (1992) found in
MCF-7 cells that P-gp restricted the accumulation of BP, and this effect could be blocked by
verapamil. Because of the contradictory results, further studies with other specific P-gp
inhibitors will be needed to clarify the role of P-gp in the placental transfer of BP.
The effects of the potential ABCG2 inhibitors, BUP and THC, on transplacental transfer
of  the  ABCG2  substrate  PhIP,  were  also  explored  in  this  study  (III). The hypothesis was
that BUP or THC would be able to increase fetal exposure to other harmful agents. In
preliminary cell experiments with BeWo cells, cellular uptake of PhIP was increased by
BUP in a similar manner as with the specific ABCG2 inhibitor, KO143. However, in the
perfusion studies with clinically achievable concentrations of BUP, the maternofetal
transfer of PhIP was not affected. The potential significance of ABCG2 in the placental
transfer of its substrates has been demonstrated in a few placental perfusion experiments.
In the short-term (2 hours) placental perfusions conducted by Feinshtein et al. (2013), the
maternofetal transfer of glyburide was increased significantly by the ABCG2 inhibitor
cannabidiol, which is a major phytocannabinoid present in marijuana. Thus, the mechanism
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behind the facilitated transfer was postulated to be inhibition of ABCG2. Similarly,
Myllynen and coworkers (2008) found that the maternofetal transfer of PhIP was increased
by inhibiting the function of the ABCG2 in term placentas.
In  further  studies  it  would  be  worthwhile  to  determine  the  expression  of  efflux-
transporters  in  the  perfused  tissue  samples  when  their  function  is  being  studied,  as  was
done by Myllynen and coworkers (2008). It has been observed that the expression of ABC-
transporters in human placenta changes during pregnancy. The amount of P-gp decreases
with the advance of gestation (Gil et al., 2005; Sun et al., 2006). Furthermore, the regulation
of P-gp in human placenta has not been thoroughly explored (reviewed in Iqbal et al.,
2012): it is known that there are also individual differences in the P-gp expression, mainly
for genetic reasons (Hemauer et al., 2010). The expression data of ABCG2 in human
placenta is somewhat controversial. There are publications claiming that the amount of
ABCG2 decreases (Meyer zu Schwabedissen et al., 2006), stays at approximately the same
level (Mathias et al., 2005), or increases with advancing gestation (Yeboah et al., 2006), but
there is agreement that it is clearly detectable in term human placentas (Myllynen et al.,
2008; Immonen et al., 2010; Javam et al., 2014; Memon et al., 2014). It is thus feasible to think
that placental efflux-transporters may restrict the transplacental transfer of its substrates
and on the other hand, the inhibition of the function of efflux-transporters could well lead
to increased fetal exposure to these substrates.
6.1.4 The effects of ethanol on transplacental transfer
It has been long known that ethanol passes through human placenta very readily (Idänpää-
Heikkilä et al., 1971; Brien et al., 1983). However, there are two reasons why it was decided
to investigate the effects of ethanol on placental perfusion (II). Many pregnant women
drink alcohol during pregnancy and expose their fetus to ethanol, and since ethanol is an
organic solvent, it may theoretically affect the transfer of other compounds. Furthermore,
there are possibilities that it exerts effects on biological membranes.
It has been shown earlier that ethanol increases the permeability and fluidity of different
cell layers (Patra et al., 2006) and reduces membrane integrity (Frischknecht and Frink,
2006; Terama et al., 2008). For example, ethanol is used to enhance skin permeation of drugs
such as estradiol, especially in patches (Williams and Barry, 2004). Recently, the effects of
ethanol on the permeability of cell layers have been studied in another cell type. Wang and
coworkers (2014) suggested that ethanol could increase the permeability of intestinal
epithelial barrier by altering the expression of two tight junction-associated proteins, ZO-1
and claudin-1. In vivo animal data is available concerning the synergistic effects of ethanol
and NDMA during pregnancy in patas monkeys (Chhabra et al., 1995). It was shown that
administration of NDMA led to the appearance of NDMA-derived adducts in placenta and
fetal liver. When ethanol was administered concurrently with NDMA, the adducts were
mainly found in other fetal tissues.
To study the potential effects of ethanol, it was combined with nicotine, NDMA, or PhIP
(II).  In the experiments in term placenta, it was found that relevant, ethanol concentrations
did not affect the transplacental transfer of the studied compounds. The perfused placentas
were obtained from non-alcoholic mothers. In real life, the maternal exposure to ethanol is
often unfortunately chronic in its nature. It would therefore have been more realistic to
perfuse placentas from mothers who had been consuming alcohol during pregnancy, since
then the chronic effects on the xenobiotic transfer could have been evaluated. Recently Lui
and coworkers (2014) reported that acute exposure to ethanol affected the function of the
first  trimester  placenta  by reducing placental  cell  growth and trophoblast  migration.  This
mechanism could well affect transplacental transfer not only in the early placenta but also
for  the  rest  of  pregnancy.  This  finding also  supports  the  recommendation that  abstinence
during pregnancy is the safest option.
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6.2 DETERMINANTS OF SUCCESS OF HUMAN PLACENTAL PERFUSION
6.2.1 Human placental perfusion as a model to study fetal exposure
A good availability of the placentas is the basis of a functional perfusion laboratory. It is
important that the number of births is adequate, the distance between hospital and
laboratory not too long, and there is good collaboration with hospital workers to ensure the
appropriate handling of the placenta already in the maternity ward. In the nearby Kuopio
University Hospital, about 2500 babies are born every year and there is excellent
collaboration with the personnel in the hospital.  To improve knowledge of midwives about
the research, seminars have been organized for the personnel of the maternity ward. It has
been also important that the donating mothers have generally been interested to participate
in this kind of research (Halkoaho et al., 2010).
In comparison to many other research methods, there are major challenges encountered
in human placental perfusion. One challenge of the perfusion studies is the low success
rate, which is mainly related to the difficulty in collecting intact tissue. However, the high
work load in placental perfusion studies is justified because the ex vivo placental perfusion
represents a unique opportunity to study different functions in valuable human tissue
retaining its original tissue structure. The last paper included in this thesis (IV) provides a
timeline with different checkpoints where problems can appear during the perfusion
procedure, starting from the delivery of the placenta to the analysis of the reference
compound antipyrine after the placental perfusion has been completed.
In this thesis, the success rate for the perfusions where preperfusion was carried out and
study substance was added to perfusion medium was 43% (38/88) (as described in the
materials and methods section). Unfortunately, an accurate number of all the received
placentas in our laboratory was not available. As a consequence, it has been decided to re-
define the protocol, and improve the perfusion form so that all details are more easily
accessible to all members of the research group. Mathiesen and coworkers (2010) have
listed their success rates during one year (202 received placentas) as follows: 92% of
received placentas passed the cannulation phase; 21% of received placentas were accepted
after the preperfusion and study compound could be added; only 15 % of received
placentas could be judged as successful perfusions. According their published data, their
success rate is about 71% when calculated similarly to ours.
The main cause for the premature interruption of a perfusion experiment is usually the
volume loss from fetal vessels to the maternal side as discussed earlier (Mathiesen et al.,
2010; Myllynen et al., 2010). Even though the success rate is rarther low, in the literature the
number of experiments in published papers has been low. Usually, only a few perfusions
have been described (Annola et al., 2008; Partanen et al., 2010). This is justified because of
the  low  variation  between  perfusions.  However,  there  is  also  one  published  study  where
only two perfusions were carried out (Zarek et al., 2013).
Perhaps the most common criticism raised against the placental perfusion studies is that
only readily available term placentas are perfused. However, the first trimester placenta
represents the time when the fetus is the most vulnerable to toxic agents because that is the
period of organogenesis. On the other hand, the thickness of placental barrier including the
number of cell layers (Benirschke et al., 2006) and the amount of protective efflux
transporters (at least P-gp, the presence of ABCG2 is more controversial) decrease towards
the end of pregnancy (Gil et al., 2005; Meyer zu Schwabedissen et al., 2006; Sun et al., 2007).
Thus  the  placental  barrier  may  be  even  more  susceptible  to  toxic  effects  at  term,  but  this
speculation obviously will need to be confirmed in further studies.
To take full advantage of the method, pre-screening of the intended study compounds is
essential, because in placental perfusion, the number of experiments that can be completed
with a tolerable workload is restricted (Myllynen et al., 2010; Göhner et al., 2014). It is
obvious that small research groups cannot afford many different laboratory methods. The
detection of various compounds from perfusion medium and perfused tissue requires
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separate methods for their analysis. Thus, collaboration with the experts from different
disciplines e.g. chemistry is important and provides relevant skills which can be exploited
by the  research group.  In  this  thesis,  all  the  studies  were  produced by collaborating with
experts as described in papers (I-IV).
In  perfusion  studies,  depending  on  the  compound,  there  may  be  a  variety  of  relevant
targets for further studies e.g. as placental biomarkers of toxicity (Vähäkangas et al., 2014).
By taking tissue samples before and after perfusions and storing them at -80°C, later
analysis is possible. For instance, these tissue samples could be used to determine mRNA
and protein expression of placental transporters and metabolizing enzymes (see e.g.
Myllynen et al., 2008; Immonen et al., 2010). Furthermore, toxic responses or release of
stress factors in human placenta could be determined. As has been shown, also the
condition of the perfused tissue can be evaluated by later histological evaluation (Partanen
et al., 2010; 2012).
An important issue in perfusion studies is the poor recovery of some compounds
because of binding to the perfusion equipment, especially to perfusion tubing, because
other  parts  of  the  equipment  are  made of  glass.  In  particular,  lipophilic  compounds have
been  problematic,  as  in  the  cases  of  BP  (I,IV) and diazepam (Myllynen and Vähäkangas,
2002). This is the reason why before conducting any actual perfusions, dummy run (empty)
perfusion without placenta should be undertaken (Annola et al., 2008; 2009). Furthermore,
it is obvious that there are tubings made of different materials, which emphasizes the need
to  use  an  empty  perfusion  with  the  same  tube  material  as  will  be  used  in  the  actual
perfusion. In vitro incubation of tubing material with the study compound offers an easier
and cheaper option where different concentrations of the study compound and different
tube materials can be studied concurrently (IV).
6.2.2 Factors affecting the success of perfusion
Although human placental perfusion has been used in laboratories all around the world for
about 50 years (Panigel et al., 1962), there are still many details relating to the perfusion
protocols that have not been studied in detail. Human placental perfusions have been
carried out in Kuopio since 2006. During almost decade a databank from over 100
perfusions has been collected and this includes the information about the placenta
(pregnancy weeks and weight), way of delivery, and details of perfusion experiments. This
data was used to discover potential factors such as placental and birth related properties
which could influence the success of perfusion experiments according to the two main
criteria: transfer of the reference compound antipyrine and volume loss (leak) from fetal to
maternal side (IV). Most published perfusion studies in the literature have been too small
to make it possible to examine the effect of placental parameters on perfusion outcome.
Only recently have larger studies emerged. A lack of significance of the way of delivery
(cesarean section or normal delivery) on the transfer of the reference compound antipyrine
has been reported by Mathiesen et al.  (2010, n=47), and Mose et al. (2012, n=93). These new
results  included in  this  thesis  (n=92)  support  the  earlier  findings.  Moreover,  it  was  found
that the leak during perfusion experiment was also not affected by the way of delivery.
Since  it  has  been  claimed  that  normal  delivery  poses  a  greater  oxidative  stress  on  the
human placenta than cesarean section (Cindrova-Davies et al., 2007), one would expect that
placentas from cesarean sections would reflect better the physiology of functional term
placenta, since those have not been subjected to stress of labor and delivery. Nonetheless
both according to literature (Mathiesen et al., 2010, Mose et al., 2012) and this present study,
it seems that in the transplacental transfer studies, it does not matter whether the placenta
has been obtained after a cesarean section or by normal vaginal delivery.
A successful perfusion can be defined by three requirements that should be met
including technical and placental tissue viability related issues. By fulfilling certain basic
conditions, it can be ensured that the perfusion experiment itself and the placental function
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have remained close to the physiological condition. The first requirement is the integrity of
the perfused area, which is controlled usually via the volume loss (leak) from fetal
circulation  to  maternal  side.  There  may  be  naturally  a  small  leak  because  of  the  high
pressure in the closed fetal circulation. This has been indicated by the finding of fetal cells
in the maternal circulation (Liou et al., 1994; Korabecna and Jirkovska, 2014). It is clear that
there are many critical steps that may damage villous structure and cause a leak in
perfusions: 1) Trauma in the placental tissue because of labor regardless of the way of birth
as has been shown in many studies (for reviews see e.g. Pienimäki, 1996; Mathiesen et al.,
2010); 2) It was noticed that the handling of placenta by midwives varies considerably while
taking  clinical  samples  according  to  normal  protocols;  3)  Different  ways  of  handling  the
placenta  by  the  researcher,  when  preparing  it  for  perfusion;  4)  Blood  clotting,  if  the  time
between delivery of the placenta and the injection of heparinized pre-perfusate is too long.
Here, a flow rate of 3 ml/h was used as the limit value for the volume loss, although in
the aflatoxin perfusions conducted by Partanen and coworkers (2010) 4 ml/h was allowed
because  aflatoxin  is  toxic  and  the  success  rate  remained  very  low  in  any  case.  In  the
literature, the limit value of volume loss in the perfusion studies has varied between 2-4
ml/h (Miller et al., 1985; Bassily et al., 1995; Mathiesen et al., 2010; Partanen et al., 2010). To
study the significance of the leak as a marker of fetal side integrity, Mathiesen et al. (2010)
have used FITC marked dextran as a control substance, because this material does not cross
biological membranes. When the leak was ǂ 3 ml/h (flow rate of the perfusion medium on
the fetal side 3 ml/min), FITC-dextran added to the fetal side was not found in the maternal
circulation after 6 hours of perfusion. However, when the leak was higher, FITC-dextran
was detected on the maternal side, evidence of the appearance of ruptures in the villous
structures. Thus, the widely accepted consensus of limit value is 3 ml/h.
The  second  requirement  for  a  successful  perfusion  is  to  confirm  the  necessary  overlap
between fetal and maternal perfused areas of the same cotyledon. In order to confirm this
already at the beginning of the perfusion, the detection of oxygen transfer from the
maternal to the fetal side has been used (Wier and Miller, 1985). If no oxygen is transferred
Mathiesen et al. (2010) have recommended changing the location of the maternal cannulae
before initiating the perfusion experiment. Another way to confirm overlap is the
maternofetal transfer of a reference compound and usually this compound is antipyrine,
because  it  is  a  freely  diffusible  compound  which  does  not  bind  to  plasma  proteins
(Schneider et al., 1972; Challier et al., 1983). It has also been used to normalize transfer data
between different placentas and between separate perfusion experiments (Ala-Kokko et al.,
1997; Myllynen et al., 2003; Mose et al., 2012). It is obvious that with two maternal cannulae
inserted through the membrane to the maternal blood space, one cannot achieve exactly
identical flow from one perfusion to the next.  However, only a few perfusions during the
history of perfusions in Kuopio have had to be discarded because of poor antipyrine
transfer.
The  third  requirement  is  the  viability  and  metabolic  activity  of  the  perfused  cotyledon
and this has been most commonly assessed by measuring glucose consumption. In the
studies included in this thesis, the glucose consumption of perfused tissue was confirmed
but  not  quantified.  Other  markers  which  have  been  used  to  confirm  the  viability  and
metabolic activity of tissue are e.g. oxygen consumption (Wier and Miller, 1985),
production of lactate (Hauguel et al., 1983; Illsley et al., 1984), production of hormones such
as human chorionic gonadotropin (hCG) and human placental lactogen (hPL) (Wier and
Miller, 1985; Bersinger et al., 1986), and placental alkaline phosphatase (PLAP) as a marker
of tissue damage (review by Mathiesen et al., 2010; Partanen et al., 2012). Of these other
markers, only oxygen levels were measured as a part of the present studies.
In this study, it was clear that leak was not affected by placental age or weight (IV). The
only statistically significant finding was that the transfer of antipyrine decreased with the
increasing age of the placenta. In the term placentas, calcifications are significantly
increased, and even clearly visible in most placentas with pregnancy weeks >41 (Jeacock et
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al., 1963; Poggi et al., 2001). In addition, the increased replacement of trophoblastic cover of
villi by fibrinoid tissue, may affect the transfer of the compounds in late pregnancy
(Benirschke et al., 2006). Based on these findings, it would be interesting to determine
whether other perfusion groups could find the same negative correlation between placental
age and antipyrine transfer. Another further area of study could be to examine the effect of
placental  and  birth  related  factors  on  the  viability  and  metabolic  activity  of  the  perfused
cotyledon.
6.2.3 Validation of human placental perfusion as a toxicity test
Human placental perfusion has not been validated as a toxicity test. The European Centre
for the Validation of Alternative Methods (ECVAM) has published a modular approach for
the validation of in vitro test systems (Hartung et al., 2004). Test modules for the validity
assessment and required information to complete these modules are described and
compared to the existing perfusion data in table 11. According to Hartung and coworkers
(2004) the determination of whether a test is suitable to enter peer-review process, can be
done when all these modules have been succesfully completed.
According to these modules one step of the pre-validation study “between-laboratory
variability” was carried out as a part of the EU-funded project, ReProTect (Myllynen et al.,
2010). This involved a re-analysis of the earlier published transfer data provided by a dual
recirculating placental perfusion for the four model compounds selected by ReProTect
perfusion group: antipyrine, benzo(a)pyrene, IQ (2-amino-3-methylimidazo(4,5-
f)quinoline), and PhIP (2-amino-1-methyl-6-phenyl-imidazo(4,5-b)pyridine). BP results
were not included because the curve fitting failed mainly due to the slow transfer rate of BP
(discussed in detail in chapter 6.1.2.). Then the amount of variability between the
participating perfusion laboratories was determined. It was found that placental transfer of
the compounds was ranked in the same order by both research groups. Recently Mose and
coworkers (2012) found that the transfer data for the same compounds perfused in different
laboratories was comparable when the results were normalized according to antipyrine
transfer. It was stated that by applying normalization, the small methodological differences
such as different flow rates, could be corrected.
Throughout the entire procedure of a placental perfusion experiment, there are many
issues that should be standardized (Vähäkangas and Myllynen, 2006). One step in the
validation process is “test definition” (Hartung et al., 2004). In the case of this perfusion
method, at least the requirements for placenta, contents of the perfusion medium,
methodological details and the criteria of successful perfusion would need to be
harmonized between different perfusion laboratories. At present, there is also no consensus
on  what  is  the  sufficient  number  of  placentas  to  be  perfused  in  view  of  the  extent  of
interindividual variation. In the case of the reference compound antipyrine, the variation is
small (IV).
This  study provided information about  the  effect  of  the  way of  delivery on commonly
used parameters of success criteria i.e. it did not matter whether the placenta originated
from cesarean section or from normal delivery when success was judged by the volume
loss from fetal to maternal circulation or antipyrine transfer (IV).  The  neutral  effect  on
antipyrine transfer had been suggested previously in a couple of studies (Mathiesen et al.,
2010; Mose et al., 2012). Furthermore, it was found that placental age did not affect the
success of perfusion. On the other hand, a negative correlation was found between
placental age and placental transfer of the reference compound antipyrine. This finding
emphasizes the importance of normalizing the transfer data of the study compound with
the simultaneously perfused reference compound.
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In their recent systematic review, comparing in vivo and  perfusion  data,  Hutson  and
coworkers (2011) have shown that by adjusting data from perfusion studies and by taking into
account differences in pH and protein binding, the values are well comparable. Their study thus
handles the “predictive capacity” of the method (Hartung et al., 2004). However, there have
been unique difficulties in perfusion studies with different compounds (Myllynen and
Vähäkangas, 2002; I), and thus this module will need to be studied further. At the same time, it
also has to be remembered that by using term placentas, the predictivity of transplacental
transfer in early pregnancy remains unclear. However, it has been speculated that because the
placental barrier becomes thinner and the amount of efflux transporter ABCB1 is greatly
reduced towards the end of pregnancy, then one could argue that placental transfer becomes
easier towards term (Etwel et al., 2014).
Many authors have proposed that placental perfusion could be used as the final stage of a
multi-tiered approach for reproductive toxicity testing (Myllynen et al., 2010; Göhner et al.,
2014; Vähäkangas et al., 2014). Because it is virtually impossible to gather in vivo human data
about placental transfer of new drugs or of known harmful compounds, placental perfusion
could be used to estimate fetal exposure in this organized human tissue. Testing for placental
kinetics  could  start  with  the  mechanistic  studies  in  a  simple  model  such  as  cell  lines  and
proceed with more laborious placental tissue explants and isolated placental primary cells, and
finally move on to transplacental transfer studies in placental perfusion (Myllynen at al., 2010;
Göhner et al., 2014). Clearly, out of all the methods using human cells or tissues, placental
perfusion is the most time consuming but it does provide the most relevant information.
Furthermore, according to the studies conducted so far, even a relatively small number of
repeated experiments seems to be sufficient in most cases. All in all, the present studies and
those from the literature provide encouragement that continuing the validation process will not
be in vain.
50
7 Summary and Conclusions
Fetal exposure to different xenobiotics during pregnancy has been shown to cause fetal
anomalies,  cancer,  and  mental  problems  later  in  life.  Thus,  it  is  obvious  that  at  least  the
exposure to the recognized harmful agents, especially smoking and ethanol should be avoided
during pregnancy. Human placental perfusion offers a model for investigating human
transplacental transfer of toxic compounds in organized human tissue without major ethical
problems. Furthermore, information can be gathered on transfer related mechanisms such as
the function of placental ABC efflux-transporters or metabolizing enzymes. The main
restrictions of the model are that due to practical reasons, only term placentas are used, the
method is laborious, and the success rate is relatively low.
This study gathered new information about the metabolism of the well-known PAH
compound benzo(a)pyrene (BP) in human placenta. Furthermore, the transplacental transfer of
BP,  ethanol,  nicotine,  and  food  carcinogens  NDMA  and  PhIP  was  confirmed.  All  the
compounds crossed human placenta, although there were differences in their transfer rates. The
additional information about the effects of placental and birth related factors on the success of
human placental perfusion was also provided using a large amount of perfusion data. Finally,
the status of the placental perfusion method used in Kuopio, was summarized according to
ECVAM´s modular validation approach.
1. The transplacental transfer of BP was confirmed in human placental perfusion
studies.  However,  the  transfer  was  significantly  slower  than  the  transfer  of  the
reference compound, antipyrine, suggesting that transfer was limited and that
passive diffusion may not be the sole mechanism. Because a well-known P-gp
inhibitor verapamil did not affect the kinetics of BP, it seems that P-gp does not
restrict the transfer of BP in term human placenta, but this speculation will need to be
confirmed in more detailed study. The recovery of BP from the perfusions varied
extensively,  although  the  amount  in  the  tissue  was  quite  stable.  This  was  probably
due to binding of the highly lipophilic BP to perfusion tubing. BPDE-DNA adducts
were found in the tissue perfused with 1µM BP but not from the tissue sample taken
before the perfusion; this is evidence that placental tissue possesses the ability to
metabolize BP. The adduct formation in human placenta was supported by the
formation of adducts in BeWo (human choriocarcinoma) cells.
2. The acute effects of clinically relevant ethanol concentrations on the transplacental
transfer of 2-amino-1-methyl-6-phenyl-imidazo(4,5-b)pyridine (PhIP), N-
nitrosodimethylamine (NDMA), and nicotine were studied in human placental
perfusion. In short-term perfusions, ethanol did not affect the kinetics of the studied
compounds. The transplacental transfer rate of ethanol was comparable with that of
the reference compound, antipyrine, reflecting the ready passage through the
placenta as described previously in the literature. Moreover, the possible effect of
ethanol  on  the  function  of  BCRP  was  studied in vitro, again with negative results.
Thus, ethanol does not affect the transplacental transfer, at least in acute conditions,
but longer-term exposure remains to be studied.
3. In the BeWo cells, the ABCG2/BCRP inhibitor buprenorphine (BUP) increased the
cellular uptake of the ABCG2 substrate PhIP as effectively as the specific ABCG2
inhibitor KO143. THC exerted a less significant effect. However, in the short-term (4h)
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placental perfusion studies, transplacental transfer of PhIP was not affected by BUP.
Taken together, it seems that fetal exposure to PhIP is not increased by
buprenorphine at the end of pregnancy. However, because the amount of ABCG2 in
human placenta decreases with the increasing gestational age, one cannot extrapolate
these results to the drug´s potential effect during early pregnancy.
4. The effect of placental age, weight of the placenta, and the way of delivery on the two
main  criteria  of  successful  perfusion  were  studied:  Volume  loss  (leak)  from  fetal  to
maternal side (accepted limit ǂ 3ml/h), and the transplacental transfer of the reference
compound antipyrine were not affected by these factors except for evidence that there
was reduced transfer of antipyrine with increasing placental age. A reduction in the
transfer of compounds towards term may occur due to structural changes in the
syncytiotrophoblast due to increasing gestational age such as increased calcification.
5. The  status  of  human  placental  perfusion  method  used  in  Kuopio  as  an in vitro test
system was estimated based on the ECVAM´s requirements to fulfil seven different
test modules. The module for test definition is incomplete, because the training set for
different  types  of  chemicals  is  insufficient  and  this  will  need  to  be  expanded  in
further  studies.  In  addition,  the  modules  for  predictive  capacity  and  applicability
domain must be regarded as incomplete. This work was a part of the studies
investigating within-laboratory variability, transferability, and between-laboratory
variability. The last module, performance standards, is difficult to complete because
there are no previously validated test systems for exactly the same purpose.
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Appendices

PLACENTAL PERFUSION FORM               Date __/__. Perfusion code________
Compound(s): 1.______________________
2.______________________
3.______________________
Placenta born (time)________ Weight of the placenta_________g   Delivery: normal/cesarean
Gestational weeks (mother):_____________
Krebs-Ringer buffer injected to umbilical vessels (time)_______
Fetal side cannulated (time)_______      Fetal perfusion started (time)______
Sample
code
Planned
sampling
Sampling
time
Sample
vol.(ml)
pH pO2 pCO2 Fetal volume
(ml) (for
leak)
F0, M0
F1, M1
F2, M2
F3, M3
F4, M4
F5, M5
F6, M6
F7, M7
F8, M8
F9, M9
Glucose at the beginning: _________mmol/l
Glucose at the end: fet.________mmol/l          mat.__________mmol/l
Fetal side end volume _________          Maternal side end volume ________
Weight of placental lobule
perfused ________g
pink area ________g          Leak:__________ml/h
Notes (structure, calcifications, perfused lobule etc.):
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Human Placental
Perfusion as a Model to
Study Fetal Exposure
The fetus is exposed to many 
chemicals during pregnancy. In 
the present study, human placental 
perfusion was used to determine 
placental toxicokinetics of several 
chemical carcinogens. All of the 
studied compounds crossed the 
placenta although there were dif-
ferences in their transfer rates. 
This study confirmed the potential 
of human placenta to metabolize 
polycyclic aromatic hydrocarbon, 
benzo(a)pyrene (BP) by indicating 
BP-diolepoxide-DNA adducts from 
perfused placental cotyledon. In ad-
dition, by analyzing a large series of 
perfusions, it was found that trans-
placental transfer may be weakened 
towards the end of pregnancy.
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